

Fractionation and protraction for radiotherapy of prost

International Journal of Radiation Oncology Biology Physics  
43, 1095-1101

DOI: 10.1016/s0360-3016(98)00438-6

Citation Report

#	ARTICLE	IF	CITATIONS
3	Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont Phase II dose-escalating trial. International Journal of Radiation Oncology Biology Physics, 2000, 47, 343-352.	0.4	104
4	Is the prostate $\hat{I}_{\pm}/\hat{I}^2$ ratio of 1.5 from Brenner & Hall a modeling artifact?. International Journal of Radiation Oncology Biology Physics, 2000, 47, 536-538.	0.4	76
5	In response to Drs. King and Mayo: low $\hat{I}_{\pm}/\hat{I}^2$ values for prostate appear to be independent of modeling details. International Journal of Radiation Oncology Biology Physics, 2000, 47, 538-539.	0.4	38
6	Analysis of biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer using dose-distribution variables and tumor control probability models. International Journal of Radiation Oncology Biology Physics, 2000, 47, 1245-1260.	0.4	39
7	Toward optimal external-beam fractionation for prostate cancer. International Journal of Radiation Oncology Biology Physics, 2000, 48, 315-316.	0.4	76
9	Regarding Nay and Gupta, IJROBP 2000;46:507-513. International Journal of Radiation Oncology Biology Physics, 2000, 48, 907.	0.4	1
10	Estimation of optimum dose per fraction for high LET radiations: Implications for proton radiotherapy. International Journal of Radiation Oncology Biology Physics, 2000, 48, 1549-1557.	0.4	19
11	A simple method of obtaining equivalent doses for use in HDR brachytherapy. International Journal of Radiation Oncology Biology Physics, 2000, 46, 507-513.	0.4	148
12	Optimal radiotherapy for prostate cancer: predictions for conventional external beam, imrt, and brachytherapy from radiobiologic models. International Journal of Radiation Oncology Biology Physics, 2000, 46, 165-172.	0.4	75
13	Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland. International Journal of Radiation Oncology Biology Physics, 2000, 46, 575-580.	0.4	123
14	Regarding chan et al. ijrobp 1999;45:265-270. International Journal of Radiation Oncology Biology Physics, 2000, 47, 539.	0.4	0
15	Normal tissue dosimetric comparison between hdr prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation. International Journal of Radiation Oncology Biology Physics, 2000, 46, 851-858.	0.4	48
16	What is the $T_{pot}$ for prostate cancer? Radiobiological implications of the equivalent outcome with 125I or 103Pd. International Journal of Radiation Oncology Biology Physics, 2000, 47, 1165-1167.	0.4	22
17	Matched-Pair Analysis of Conformal High-Dose-Rate Brachytherapy Boost Versus External-Beam Radiation Therapy Alone for Locally Advanced Prostate Cancer. Journal of Clinical Oncology, 2000, 18, 2869-2880.	0.8	116
18	Radiation Endocrine Action in Prostate Cancer. Journal of Clinical Oncology, 2000, 18, 4004-4005.	0.8	0
19	Infrequent Involvement of the Anterior Base in Low-risk Patients with Clinically Localized Prostate Cancer and Its Possible Significance in Definitive Radiation Therapy. Japanese Journal of Clinical Oncology, 2000, 30, 126-130.	0.6	19
20	Biological Aspects of Conformal Therapy. Acta Oncologica, 2000, 39, 569-577.	0.8	21
21	High dose rate brachytherapy boost treatment in radical radiotherapy for prostate cancer. Radiotherapy and Oncology, 2000, 57, 285-288.	0.3	27

#	ARTICLE	IF	CITATIONS
22	The required number of treatment imaging days for an effective off-line correction of systematic errors in conformal radiotherapy of prostate cancer – a radiobiological analysis. <i>Radiotherapy and Oncology</i> , 2001, 61, 143-150.	0.3	34
23	A theoretical investigation into the role of tumour radiosensitivity, clonogen repopulation, tumour shrinkage and radionuclide RBE in permanent brachytherapy implants of $^{125}\text{I}$ and $^{103}\text{Pd}$ . <i>Physics in Medicine and Biology</i> , 2001, 46, 2557-2569.	1.6	59
24	Biological Factors Influencing Optimum Fractionation in Radiation Therapy. <i>Acta Oncologica</i> , 2001, 40, 712-717.	0.8	120
25	Inverse planning anatomy-based dose optimization for HDR-brachytherapy of the prostate using fast simulated annealing algorithm and dedicated objective function. <i>Medical Physics</i> , 2001, 28, 773-779.	1.6	223
26	Radiation for prostate cancer. <i>Lancet Oncology</i> , The, 2001, 2, 73-81.	5.1	13
27	Locally advanced prostate cancer. <i>Current Treatment Options in Oncology</i> , 2001, 2, 403-411.	1.3	10
28	Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: A feasibility report. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 61-69.	0.4	234
29	In response to Dr. Logue et al.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 1522-1523.	0.4	1
30	Is $\hat{\alpha}/\hat{\beta}^2$ for prostate tumors really low?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 1021-1031.	0.4	612
31	Is the $\hat{\alpha}/\hat{\beta}^2$ ratio for prostate cancer low?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 1-3.	0.4	82
32	Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 988-993.	0.4	114
33	Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer: pitfalls in deducing radiobiologic parameters for tumors from clinical data. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 1064-1080.	0.4	81
34	The Role of Biologically Effective Dose (BED) in Clinical Oncology. <i>Clinical Oncology</i> , 2001, 13, 71-81.	0.6	122
35	A simple analytic derivation suggests that prostate cancer $\hat{\alpha}/\hat{\beta}^2$ ratio is low. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 213-214.	0.4	164
36	Toxicity and Health-related Quality of Life During and After High Dose Rate Brachytherapy Followed by External Beam Radiotherapy for Prostate Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2001, 31, 541-547.	0.6	30
37	Importance of cell proliferative state and potentially lethal damage repair on radiation effectiveness: Implications for combined tumor treatments (Review). <i>International Journal of Oncology</i> , 2001, 19, 247-56.	1.4	32
38	Results of acoustic neuroma radiosurgery: an analysis of 5 years' experience using current methods. <i>Journal of Neurosurgery</i> , 2001, 94, 1-6.	0.9	441
39	Evaluation of external beam radiotherapy and brachytherapy for localized prostate cancer using equivalent uniform dose. <i>Medical Physics</i> , 2002, 30, 34-40.	1.6	52

#	ARTICLE	IF	CITATIONS
41	Helical Tomotherapy: An Innovative Technology and Approach to Radiation Therapy. <i>Technology in Cancer Research and Treatment</i> , 2002, 1, 311-316.	0.8	149
42	The Influence of Percentage of Preradiation Needle Biopsies With Adenocarcinoma and Total Radiation Dose on the Pathologic Response of Unfavorable Prostate Adenocarcinoma. <i>American Journal of Clinical Pathology</i> , 2002, 117, 927-934.	0.4	1
43	Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy. <i>British Journal of Radiology</i> , 2002, 75, 151-161.	1.0	65
44	The Use of Rectal Balloon During the Delivery of Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2002, 8, 476-483.	1.0	75
45	Scoring of treatment-related late effects in prostate cancer. <i>Radiotherapy and Oncology</i> , 2002, 65, 109-121.	0.3	44
46	Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. <i>Seminars in Radiation Oncology</i> , 2002, 12, 81-94.	1.0	163
47	A Review of intensity modulated radiation therapy: Incorporating a report on the seventh education workshop of the ACPSEM ACT/NSW branch. <i>Australasian Physical and Engineering Sciences in Medicine</i> , 2002, 25, 91-101.	1.4	1
48	Fractionated stereotactic radiotherapy for acoustic neuromas. <i>Acta Neurochirurgica</i> , 2002, 144, 1249-1254.	0.9	29
49	Clinical experience with intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of rectal balloon for prostate immobilization. <i>Medical Dosimetry</i> , 2002, 27, 105-113.	0.4	52
50	Dose distribution and morbidity after high dose rate brachytherapy for prostate cancer: Influence of V150 and V200 parameters. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2002, 46, 384-389.	0.6	17
51	Direct evidence that prostate tumors show high sensitivity to fractionation (low $\hat{\alpha}/\hat{\beta}^2$ ratio), similar to late-responding normal tissue. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 6-13.	0.4	612
52	Reduction of rectal dose by integration of the boost in the large-field treatment plan for prostate irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 254-265.	0.4	57
53	In response to Drs. Dale and Jones. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 1428.	0.4	9
54	Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 316-327.	0.4	201
55	Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 904-912.	0.4	122
56	In response to Dr. Lee. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 1393.	0.4	3
57	The prospects for new treatments for prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 3-5.	0.4	45
58	Is the $\hat{\alpha}/\hat{\beta}^2$ for prostate tumors really low? In regard to Fowler et al., <i>IJROBP</i> 2001;50:1021-1031. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 1427-1428.	0.4	23

#	ARTICLE	IF	CITATIONS
59	Biologically effective dose for permanent prostate brachytherapy taking into account postimplant edema. International Journal of Radiation Oncology Biology Physics, 2002, 53, 422-433.	0.4	20
60	Fractionated stereotactic radiotherapy for acoustic neuromas. International Journal of Radiation Oncology Biology Physics, 2002, 54, 500-504.	0.4	92
61	Early clinical experience with anatomy-based inverse planning dose optimization for high-dose-rate boost of the prostate. International Journal of Radiation Oncology Biology Physics, 2002, 54, 86-100.	0.4	67
62	Yes, the $\hat{\alpha}/\hat{\beta}^2$ ratio for prostate cancer is low or "methinks the lady doth protest too much" about a low $\hat{\alpha}/\hat{\beta}^2$ that is! International Journal of Radiation Oncology Biology Physics, 2002, 54, 626-627.	0.4	15
63	In response to Drs. King and Fowler. International Journal of Radiation Oncology Biology Physics, 2002, 54, 627-628.	0.4	7
64	Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2002, 54, 107-118.	0.4	25
65	LDR vs. HDR brachytherapy for localized prostate cancer. Brachytherapy, 2002, 1, 219-226.	0.2	46
67	Radiation therapy dose escalation for prostate cancer: a rationale for IMRT. World Journal of Urology, 2003, 21, 200-208.	1.2	78
68	Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy. World Journal of Urology, 2003, 21, 275-289.	1.2	9
69	Feasibility of amifostine administration in conjunction with high-dose rate brachytherapy. Seminars in Oncology, 2003, 30, 49-57.	0.8	1
70	High-dose-rate brachytherapy as monotherapy for localized prostate cancer: A retrospective analysis with special focus on tolerance and chronic toxicity. International Journal of Radiation Oncology Biology Physics, 2003, 56, 213-220.	0.4	72
71	Prediction of the benefits from dose-escalated hypofractionated intensity-modulated radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics, 2003, 56, 199-207.	0.4	42
72	Image guidance for precise conformal radiotherapy. International Journal of Radiation Oncology Biology Physics, 2003, 56, 89-105.	0.4	445
73	What hypofractionated protocols should be tested for prostate cancer?. International Journal of Radiation Oncology Biology Physics, 2003, 56, 1093-1104.	0.4	292
74	Low $\hat{\alpha}/\hat{\beta}^2$ ratio for prostate cancer: in response to Dr. Fowler et al.. International Journal of Radiation Oncology Biology Physics, 2003, 57, 595-596.	0.4	21
75	Impact of prolonged fraction delivery times on tumor control: A note of caution for intensity-modulated radiation therapy (IMRT). International Journal of Radiation Oncology Biology Physics, 2003, 57, 543-552.	0.4	192
76	Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: Implications for the $\hat{\alpha}/\hat{\beta}^2$ ratio. International Journal of Radiation Oncology Biology Physics, 2003, 57, 391-401.	0.4	210
77	The impact of geometric uncertainty on hypofractionated external beam radiation therapy of prostate cancer. International Journal of Radiation Oncology Biology Physics, 2003, 57, 833-842.	0.4	28

#	ARTICLE	IF	CITATIONS
78	Intrafractional stability of the prostate using a stereotactic radiotherapy technique. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1285-1291.	0.4	62
79	Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1254-1259.	0.4	141
80	How low is the $\hat{\alpha}/\hat{\beta}^2$ ratio for prostate cancer?. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1116-1121.	0.4	86
81	Short course radiation therapy for elderly cancer patients.. Critical Reviews in Oncology/Hematology, 2003, 45, 305-311.	2.0	30
82	Treatment of localized prostate cancer using a combination of high dose rate Iridium-192 brachytherapy and external beam irradiation: Initial Australian experience. Journal of Medical Imaging and Radiation Oncology, 2003, 47, 152-160.	0.6	10
84	How low is the $\hat{\alpha}/\hat{\beta}^2$ ratio for prostate cancer?. International Journal of Radiation Oncology Biology Physics, 2003, 55, 194-203.	0.4	288
85	How low is the $\hat{\alpha}/\hat{\beta}^2$ ratio for prostate cancer? in regard to Wang et al., IJROBP 2003;55:194-203. International Journal of Radiation Oncology Biology Physics, 2003, 57, 593-595.	0.4	26
86	The low $\hat{\alpha}/\hat{\beta}^2$ ratio for prostate cancer: What does the clinical outcome of HDR brachytherapy tell us?. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1101-1108.	0.4	103
87	Hypofractionation for prostate cancer radiotherapy-what are the issues?. International Journal of Radiation Oncology Biology Physics, 2003, 57, 912-914.	0.4	87
88	Should single or distributed parameters be used to explain the steepness of tumour control probability curves?. Physics in Medicine and Biology, 2003, 48, 387-397.	1.6	62
89	The effects of delays in radiotherapy treatment on tumour control. Physics in Medicine and Biology, 2003, 48, 139-155.	1.6	103
90	Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Radiotherapy and Oncology, 2003, 66, 167-172.	0.3	57
92	16 The role of NTCP models in the Optimisation Of IMRT. Radiotherapy and Oncology, 2003, 68, S6-S7.	0.3	1
93	The influence of brachytherapy dose heterogeneity on estimates of $\hat{\alpha}/\hat{\beta}$ for prostate cancer. Physics in Medicine and Biology, 2003, 48, 507-522.	1.6	25
94	Radical radiotherapy for prostate cancer. Cancer Treatment Reviews, 2003, 29, 161-169.	3.4	16
95	Fractionated stereotactic radiotherapy for acoustic neuromas: preservation of function versus size. Journal of Clinical Neuroscience, 2003, 10, 48-52.	0.8	39
96	Dual radiobiological interpretations of retrospective clinical data: the time factor. International Journal of Radiation Biology, 2003, 79, 503-509.	1.0	5
97	Radiobiological Analysis of Tissue Responses Following Radiosurgery. Technology in Cancer Research and Treatment, 2003, 2, 87-92.	0.8	45

#	ARTICLE	IF	CITATIONS
98	CyberKnife Radiotherapy for Localized Prostate Cancer: Rationale and Technical Feasibility. <i>Technology in Cancer Research and Treatment</i> , 2003, 2, 25-29.	0.8	148
99	Comparison of $\hat{I}_1/\hat{I}_2$ estimates from homogeneous (individual) and heterogeneous (population) tumor control models for early stage prostate cancer. <i>Medical Physics</i> , 2003, 30, 2832-2848.	1.6	20
100	Is the Renal Dosimetry for [90Y-DOTA0, Tyr3]Octreotide Accurate Enough to Predict Thresholds for Individual Patients?. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003, 18, 619-625.	0.7	31
101	Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations. <i>Physics in Medicine and Biology</i> , 2003, 48, 2753-2765.	1.6	44
102	Reduction in Acute Morbidity Using Hypofractionated Intensity-Modulated Radiation Therapy Assisted with a Fluoroscopic Real-Time Tumor-Tracking System for Prostate Cancer. <i>Cancer Journal (Sudbury, Tj ETQq0 0 0 ngB /Overl</i>	1.0	42
103	Development of a simultaneous boost IMRT class solution for a hypofractionated prostate cancer protocol. <i>British Journal of Radiology</i> , 2004, 77, 377-386.	1.0	43
104	TCP isoeffect analysis using a heterogeneous distribution of radiosensitivity. <i>Medical Physics</i> , 2004, 31, 1176-1182.	1.6	18
105	The impact of daily shifts on prostate IMRT dose distributions. <i>Medical Physics</i> , 2004, 31, 2845-2848.	1.6	55
106	prostate brachytherapy: a review of current practice. <i>Journal of Radiotherapy in Practice</i> , 2004, 4, 86-101.	0.2	4
107	Intensity Modulated Radiation Therapy (IMRT) in the Management of Prostate Cancer. <i>Cancer Investigation</i> , 2004, 22, 913-924.	0.6	15
108	Clinical effects in a cohort of cancer patients overexposed during external beam pelvic radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 538-550.	0.4	8
109	Application of the linear-quadratic model to combined modality radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 228-241.	0.4	42
110	Fractionation and late rectal toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1013-1015.	0.4	187
111	Recovery from sublethal damage during intermittent exposures in cultured tumor cells: implications for dose modification in radiosurgery and imrt. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 1484-1490.	0.4	87
114	Evaluation of therapeutic potential of heavy ion therapy for patients with locally advanced prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 89-97.	0.4	41
115	Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 735-742.	0.4	61
116	Doseâ€‘volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 1540-1548.	0.4	32
117	External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 372-379.	0.4	23

#	ARTICLE	IF	CITATIONS
118	Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics, 2004, 59, 684-690.	0.4	62
119	In response to Dr. Orton. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1637-1639.	0.4	4
120	Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. International Journal of Radiation Oncology Biology Physics, 2004, 59, 267-284.	0.4	143
121	Assessment of i-125 prostate implants by tumor bioeffect. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1405-1413.	0.4	25
122	Rectal bleeding after hypofractionated radiotherapy for prostate cancer: Correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1033-1039.	0.4	92
123	Prostate implant evaluation using tumour control probability—the effect of input parameters. Physics in Medicine and Biology, 2004, 49, 3649-3664.	1.6	18
124	Comparison of in vitro and in vivo $\hat{\Lambda}/\hat{\Lambda}^2$ ratios for prostate cancer. Physics in Medicine and Biology, 2004, 49, 4477-4491.	1.6	95
125	Late Urinary Morbidity With High Dose Prostate Brachytherapy as a Boost to Conventional External Beam Radiation Therapy for Local and Locally Advanced Prostate Cancer. Journal of Urology, 2004, 171, 1105-1108.	0.2	33
126	The Effect of Technique and Fraction Size on Acute Toxicity in Patients Receiving High Precision Radiation Therapy for Prostate Cancer. Journal of Medical Imaging and Radiation Sciences, 2004, 35, 21-27.	0.1	0
127	59 Brachytherapy as monotherapy in localised prostate cancer, permanent seed implantation or high dose rate ?. Radiotherapy and Oncology, 2004, 71, S29-S30.	0.3	3
128	Evaluation of the new cesium-131 seed for use in low-energy x-ray brachytherapy. Medical Physics, 2004, 31, 1529-1538.	1.6	89
129	Clinical and physical quality assurance for intensity modulated radiotherapy of prostate cancer. Radiotherapy and Oncology, 2004, 71, 319-325.	0.3	45
130	Impact of Elapsed Treatment Time on Outcome of External-Beam Radiation Therapy for Localized Carcinoma of the Prostate. Cancer Journal (Sudbury, Mass ), 2004, 10, 349-356.	1.0	33
131	Comments on 'Comparison of in vitro and in vivo $\hat{\Lambda}/\hat{\Lambda}^2$ ratios for prostate cancer'. Physics in Medicine and Biology, 2005, 50, L1-L4.	1.6	10
132	Reply to 'Comments on 'Comparison of in vitro and in vivo $\hat{\Lambda}/\hat{\Lambda}^2$ ratios for prostate cancer''. Physics in Medicine and Biology, 2005, 50, L5-L8.	1.6	6
133	Methodology for biologically-based treatment planning for combined low-dose-rate (permanent) Tj ETQq1 1 0.784314 rgBT /Overlock Radiation Oncology Biology Physics, 2005, 61, 702-713.	0.4	23
134	High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. International Journal of Radiation Oncology Biology Physics, 2005, 61, 1306-1316.	0.4	234
135	Modeling prostate cancer: In regards to Nahum et al. (Int J Radiat Oncol Biol Phys 2003;57:391-401). International Journal of Radiation Oncology Biology Physics, 2005, 61, 309-310.	0.4	17



#	ARTICLE	IF	CITATIONS
136	In response to Dr. Wang et al.. International Journal of Radiation Oncology Biology Physics, 2005, 61, 310-311.	0.4	4
137	Prevention of pterygium recurrence by postoperative single-dose $\hat{I}^2$ -irradiation: A prospective randomized clinical double-blind trial. International Journal of Radiation Oncology Biology Physics, 2005, 61, 311-312.	0.4	0
138	Impact of tumor repopulation on radiotherapy planning. International Journal of Radiation Oncology Biology Physics, 2005, 61, 220-227.	0.4	59
139	Individualized planning target volumes for intrafraction motion during hypofractionated intensity-modulated radiotherapy boost for prostate cancer. International Journal of Radiation Oncology Biology Physics, 2005, 62, 418-425.	0.4	77
140	Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. International Journal of Radiation Oncology Biology Physics, 2005, 62, 706-713.	0.4	138
141	Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. International Journal of Radiation Oncology Biology Physics, 2005, 61, 1251-1257.	0.4	63
142	Radiobiological parameters suitable for modeling individual outcomes cannot be obtained by analyzing heterogeneous population data with homogeneous tumor control model: In regard to Dâ€™Souza et al. (Int J Radiat Oncol Biol Phys 2004;58:1540â€“1548). International Journal of Radiation Oncology Biology Physics, 2005, 62, 298-299.	0.4	1
143	Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1463-1468.	0.4	174
144	Novel Therapies in Bladder Cancer. Clinical Oncology, 2005, 17, 524-538.	0.6	8
145	Radiotherapeutic Techniques for Prostate Cancer, Dose Escalation and Brachytherapy. Clinical Oncology, 2005, 17, 560-571.	0.6	50
146	Rectal wall sparing by dosimetric effect of rectal balloon used during Intensity-Modulated Radiation Therapy (IMRT) for prostate cancer. Medical Dosimetry, 2005, 30, 25-30.	0.4	55
147	Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: Results of a matched pair analysis. Prostate, 2005, 62, 54-60.	1.2	17
148	Radical Radiotherapy for Prostate Cancer. , 2005, , 48-59.		0
149	Steepness of the radiation dose-response curve for dose-per-fraction escalation keeping the number of fractions fixed. Acta OncolÃ³gica, 2005, 44, 825-828.	0.8	14
150	Latest developments in local treatment: radiotherapy for early breast cancer. Annals of Oncology, 2005, 16, ii170-ii173.	0.6	5
151	Combined curative radiotherapy including HDR brachytherapy and androgen deprivation in localized prostate cancer: A prospective assessment of acute and late treatment toxicity. Acta OncolÃ³gica, 2005, 44, 633-643.	0.8	13
152	Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer. Journal of Clinical Oncology, 2005, 23, 6132-6138.	0.8	331
153	Radiotherapy in the Management of Clinically Localized Prostate Cancer: Evolving Standards, Consensus, Controversies and New Directions. Journal of Clinical Oncology, 2005, 23, 8176-8185.	0.8	50

#	ARTICLE	IF	CITATIONS
154	Limitations of a TCP model incorporating population heterogeneity. <i>Physics in Medicine and Biology</i> , 2005, 50, 3571-3588.	1.6	10
155	Effect of patient variation on standard- and hypo-fractionated radiotherapy of prostate cancer. <i>Physics in Medicine and Biology</i> , 2005, 50, 1483-1492.	1.6	3
156	Multidisciplinary treatment of synchronous primary rectal and prostate cancers. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 271-274.	4.3	15
157	Image-guided adaptive radiation therapy (IGART): Radiobiological and dose escalation considerations for localized carcinoma of the prostate. <i>Medical Physics</i> , 2005, 32, 2193-2203.	1.6	49
158	Is the alpha/beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. <i>Radiotherapy and Oncology</i> , 2005, 75, 74-82.	0.3	74
159	The $\alpha/\beta$ ratio for prostate cancer: What is it, really?. <i>Radiotherapy and Oncology</i> , 2005, 76, 1-3.	0.3	149
160	The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. <i>Acta Oncologica</i> , 2005, 44, 265-276.	0.8	311
163	The potential of proton beam radiation therapy in prostate cancer, other urological cancers and gynaecological cancers. <i>Acta Oncologica</i> , 2005, 44, 890-895.	0.8	12
164	Fundamental form of a population TCP model in the limit of large heterogeneity. <i>Medical Physics</i> , 2006, 33, 1634-1642.	1.6	21
165	Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: Report on acute toxicity. <i>Radiotherapy and Oncology</i> , 2006, 80, 78-81.	0.3	70
166	High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer. <i>Radiotherapy and Oncology</i> , 2006, 80, 62-68.	0.3	74
167	Radiotherapy in the Management of Common Genitourinary Malignancies. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 321-346.	0.9	2
168	Efficacy of High Dose Per Fraction Radiation for Implanted Human Prostate Cancer in a Nude Mouse Model. <i>Journal of Urology</i> , 2006, 175, 1932-1936.	0.2	27
169	Update on Radiation Therapy in Prostate Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 857-878.	0.9	5
170	CyberKnife for the Treatment of Nonmetastatic Prostate Cancer: Preliminary Results. <i>Korean Journal of Urology</i> , 2006, 47, 1172.	0.2	2
171	Improving the morbidity of anorectal injury from pelvic radiotherapy. <i>Colorectal Disease</i> , 2006, 8, 2-10.	0.7	12
172	A prospective dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer: Evidence of hypofractionation efficacy?. <i>Brachytherapy</i> , 2006, 5, 256-261.	0.2	14
173	Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 518-526.	0.4	242

#	ARTICLE	IF	CITATIONS
174	Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 527-533.	0.4	221
175	Evaluation of image-guided radiation therapy (IGRT) technologies and their impact on the outcomes of hypofractionated prostate cancer treatments: A radiobiologic analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 289-300.	0.4	71
176	Disease-specific survival following the brachytherapy management of prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 810-816.	0.4	72
177	Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 65-72.	0.4	41
178	IMRT boost dose planning on dominant intraprostatic lesions: Gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 291-303.	0.4	168
179	Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 982-989.	0.4	32
180	Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: Consequential late damage. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 3-10.	0.4	141
181	Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1084-1091.	0.4	53
182	In regards to Roach et al. defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOGâ€“ASTRO Phoenix Consensus Conference ( <i>Int J Radiat Oncol Biol Phys</i> 2006;65:965â€“974). <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1274.	0.4	6
183	2670. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, S581-S582.	0.4	1
184	In reply to Drs. Russi et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1274.	0.4	0
185	Adjuvant malignant mesothelioma radiotherapy: How many difficulties! In regard to: Allen et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma ( <i>Int J Radiat Oncol Biol Phys</i> ) Tj ETQq1 1 0.784314 rgBT /Overlock 10 TF pleurectomy/decortication for malignant pleural mesothelioma ( <i>Int J Radiat Oncol Biol Phys</i> ) Tj ETQq1 1 0.784314 rgBT /Overlock 10 TF	0.4	0
186	Hypofractionated Conformal HDR Brachytherapy in Hormone NaÃ“ve Men with Localized Prostate Cancer. <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 135-141.	1.0	52
188	Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. <i>Brachytherapy</i> , 2006, 5, 157-164.	0.2	59
189	The impact on oncology of the interaction of radiation therapy and radiobiology. <i>Clinical and Translational Oncology</i> , 2006, 8, 83-93.	1.2	7
190	Acute and late genitourinary toxicity of conformal radiotherapy for prostate cancer. <i>Radiation Medicine</i> , 2006, 24, 553-559.	0.8	8
191	High-dose-rate brachytherapy combined with long-term hormonal therapy for high-risk prostate cancer: Results of a retrospective analysis. <i>Radiation Medicine</i> , 2006, 24, 58-64.	0.8	6
192	Dose escalation to combat hypoxia in prostate cancer: a radiobiological study on clinical data. <i>British Journal of Radiology</i> , 2006, 79, 905-911.	1.0	35

#	ARTICLE	IF	CITATIONS
193	External beam radiotherapy boosts to reduce the impact caused by edema in prostate permanent seed implants. <i>Physics in Medicine and Biology</i> , 2006, 51, 2267-2277.	1.6	6
194	Development of radiobiology for oncology—a personal view. <i>Physics in Medicine and Biology</i> , 2006, 51, R263-R286.	1.6	56
195	Clinical Implementation of Adaptive Helical Tomotherapy: A Unique Approach to Image-Guided Intensity Modulated Radiotherapy. <i>Technology in Cancer Research and Treatment</i> , 2006, 5, 465-479.	0.8	83
196	Practical Time-Dose Evaluations, or How to Stop Worrying and Learn to Love Linear Quadratics. , 2006, , 3-31.		10
197	Single Course IMRT Plan to Deliver 45 Gy to Seminal Vesicles and 81 Gy to Prostate in 45 Fractions. <i>Technology in Cancer Research and Treatment</i> , 2006, 5, 503-511.	0.8	2
198	Biological dose volume histograms during conformal hypofractionated accelerated radiotherapy for prostate cancer. <i>Medical Physics</i> , 2006, 34, 76-80.	1.6	7
199	The best radiotherapy for the treatment of prostate cancer involves hypofractionation. <i>Medical Physics</i> , 2006, 33, 3081-3084.	1.6	17
200	Effect of edema, relative biological effectiveness, and dose heterogeneity on prostate	1.6	23
202	Effects of seed migration on post-implant dosimetry of prostate brachytherapy. <i>Medical Physics</i> , 2007, 34, 471-480.	1.6	32
203	Prostate Cancer Therapy with Stereotactic Body Radiation Therapy. <i>Frontiers of Radiation Therapy and Oncology</i> , 2007, 40, 395-406.	1.4	23
204	Radiotherapy and hormonal treatment. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 177-188.	2.2	0
205	Biologically-equivalent dose and long-term survival time in radiation treatments. <i>Physics in Medicine and Biology</i> , 2007, 52, 6355-6362.	1.6	20
206	High Dose Rate Brachytherapy as a Boost for the Treatment of Localized Prostate Cancer. <i>Journal of Urology</i> , 2007, 177, 123-127.	0.2	73
207	Is the $\hat{\alpha}/\hat{\beta}^2$ Value for Prostate Tumours Low Enough to be Safely Used in Clinical Trials?. <i>Clinical Oncology</i> , 2007, 19, 289-301.	0.6	156
208	Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: The University of California—San Francisco experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1106-1112.	0.4	136
209	$\hat{\alpha}/\hat{\beta}^2$ ratio: A dose range dependence study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 587-593.	0.4	39
210	Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1099-1105.	0.4	356
211	Use of Individual Fraction Size Data from 3756 Patients to Directly Determine the $\hat{\alpha}/\hat{\beta}^2$ Ratio of Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 24-33.	0.4	153

#	ARTICLE	IF	CITATIONS
212	Moderately Low Alpha/Beta Ratio for Rectal Cancer May Best Explain the Outcome of Three Fractionation Schedules of Preoperative Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 793-799.	0.4	38
213	Phase II Trial of Hypofractionated Image-Guided Intensity-Modulated Radiotherapy for Localized Prostate Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1084-1089.	0.4	139
214	Analytic Investigation Into Effect of Population Heterogeneity on Parameter Ratio Estimates. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1323-1330.	0.4	8
215	Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study. <i>Radiation Oncology</i> , 2007, 2, 29.	1.2	38
216	Prostate Cancer: Biological Dose Considerations and Constraints in Tele- and Brachytherapy. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 14-15.	1.0	8
217	Hypofractionation in radiotherapy. <i>Clinical and Translational Oncology</i> , 2007, 9, 21-27.	1.2	8
218	The effect of positional realignment on dose delivery to the prostate and organs-at-risk for 3DCRT. <i>Medical Dosimetry</i> , 2007, 32, 1-6.	0.4	5
219	Investigation of Linac-Based Image-Guided Hypofractionated Prostate Radiotherapy. <i>Medical Dosimetry</i> , 2007, 32, 71-79.	0.4	21
220	Comparing two strategies of dynamic intensity modulated radiation therapy (dIMRT) with 3-dimensional conformal radiation therapy (3DCRT) in the hypofractionated treatment of high-risk prostate cancer. <i>Radiation Oncology</i> , 2008, 3, 1.	1.2	31
221	Does Intensity Modulated Radiation Therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?. <i>Radiation Oncology</i> , 2008, 3, 3.	1.2	33
222	A Comparison of Treatment Planning Techniques Used in Two Randomised UK External Beam Radiotherapy Trials for Localised Prostate Cancer. <i>Clinical Oncology</i> , 2008, 20, 15-21.	0.6	41
223	Dosimetric characterization of <sup>142</sup> Pr glass seeds for brachytherapy. <i>Applied Radiation and Isotopes</i> , 2008, 66, 441-449.	0.7	19
224	Phase I/II Study of a Five-fraction Hypofractionated Accelerated Radiotherapy Treatment for Low-risk Localised Prostate Cancer: Early Results of pHART3. <i>Clinical Oncology</i> , 2008, 20, 729-737.	0.6	74
225	Combined Hypofractionated Radiation and Hormone Therapy for the Treatment of Intermediate-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 58-63.	0.4	13
226	On the Need to Compensate for Edema-Induced Dose Reductions in Preplanned <sup>131</sup> Cs Prostate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 303-310.	0.4	13
227	Estimate of Radiobiologic Parameters From Clinical Data for Biologically Based Treatment Planning for Liver Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 900-907.	0.4	58
228	The Effect of Changing Technique, Dose, and PTV Margin on Therapeutic Ratio During Prostate Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1057-1064.	0.4	23
229	A Phase II Study of High-Dose-Rate Afterloading Brachytherapy as Monotherapy for the Treatment of Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 441-446.	0.4	72

#	ARTICLE	IF	CITATIONS
230	Acute Toxicity After Hypofractionated Conformal Radiotherapy for Localized Prostate Cancer: Nonrandomized Contemporary Comparison With Standard Fractionation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 770-776.e1.	0.4	27
231	Reporting Late Rectal Toxicity in Prostate Cancer Patients Treated With Curative Radiation Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 777-781.	0.4	24
232	Comparison of Dosimetric and Biologic Effective Dose Parameters for Prostate and Urethra Using <sup>131</sup> Cs and <sup>125</sup> I for Prostate Permanent Implant Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 247-254.	0.4	17
233	CyberKnife Treatment of Prostate Cancer: A Reply to Bentzen and Wasserman. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 14-18.	0.4	4
234	Balancing on a Knife's Edge: Evidence-Based Medicine and the Marketing of Health Technology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 12-14.	0.4	10
235	Pelvic Lymph Node Irradiation for Prostate Cancer: Who, Why, and When?. <i>Seminars in Radiation Oncology</i> , 2008, 18, 35-40.	1.0	16
236	Hypofractionation for Prostate Cancer: A Critical Review. <i>Seminars in Radiation Oncology</i> , 2008, 18, 41-47.	1.0	93
237	The Linear-Quadratic Model Is an Appropriate Methodology for Determining Isoeffective Doses at Large Doses Per Fraction. <i>Seminars in Radiation Oncology</i> , 2008, 18, 234-239.	1.0	457
238	Rationale, Conduct, and Outcome Using Hypofractionated Radiotherapy in Prostate Cancer. <i>Seminars in Radiation Oncology</i> , 2008, 18, 249-256.	1.0	80
239	Advanced Image-Guided External Beam Radiotherapy. <i>Cancer Treatment and Research</i> , 2008, 139, 7-39.	0.2	6
240	A theoretical framework for prescribing radiotherapy dose distributions using patient-specific biological information. <i>Medical Physics</i> , 2008, 35, 4599-4611.	1.6	29
241	Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. <i>Radiotherapy and Oncology</i> , 2008, 88, 46-52.	0.3	45
242	Hypofractionated adjuvant radiotherapy with helical Tomotherapy after radical prostatectomy: Planning data and toxicity results of a Phase II study. <i>Radiotherapy and Oncology</i> , 2008, 88, 26-33.	0.3	39
243	Patterns of relapse following radiotherapy for differentiated thyroid cancer: Implication for target volume delineation. <i>Radiotherapy and Oncology</i> , 2008, 89, 105-113.	0.3	46
244	Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. <i>Lancet Oncology</i> , The, 2008, 9, 367-375.	5.1	269
245	A mathematical approach for evaluating the influence of dose heterogeneity on TCP for prostate cancer brachytherapy treatment. <i>Physics in Medicine and Biology</i> , 2008, 53, 5045-5059.	1.6	10
246	In vitro determination of radiation sensitivity parameters for DU-145 prostate cancer cells. <i>International Journal of Radiation Biology</i> , 2008, 84, 515-522.	1.0	11
247	Radiobiology, Principle and Technique of Radiosurgery. <i>Progress in Neurological Surgery</i> , 2008, 21, 32-42.	1.3	24

#	ARTICLE	IF	CITATIONS
248	Technology Insight: combined external-beam radiation therapy and brachytherapy in the management of prostate cancer. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 668-676.	4.3	7
249	Methods to calculate normal tissue complication and tumour control probabilities for fractionated inhomogeneous dose distribution of intensity-modulated radiation therapy. <i>Journal of Radiotherapy in Practice</i> , 2008, 7, 151-157.	0.2	1
250	Association of Single Nucleotide Polymorphisms in SOD2, XRCC1 and XRCC3 with Susceptibility for the Development of Adverse Effects Resulting from Radiotherapy for Prostate Cancer. <i>Radiation Research</i> , 2008, 170, 49-59.	0.7	81
251	Designing equivalent treatment regimens for prostate radiotherapy based on equivalent uniform dose. <i>British Journal of Radiology</i> , 2008, 81, 59-68.	1.0	9
252	Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules. <i>British Journal of Radiology</i> , 2008, 81, 549-563.	1.0	35
253	Is it beneficial to selectively boost high-risk tumor subvolumes? A comparison of selectively boosting high-risk tumor subvolumes versus homogeneous dose escalation of the entire tumor based on equivalent EUD plans. <i>Acta Oncologica</i> , 2008, 47, 906-916.	0.8	26
254	Effect of radiation protraction in intensity-modulated radiation therapy with direct aperture optimization: a phantom study. <i>Physics in Medicine and Biology</i> , 2008, 53, 3279-3292.	1.6	17
255	Simulated real time image guided intrafraction tracking and delivery for hypofractionated prostate IMRT. <i>Medical Physics</i> , 2008, 35, 4041-4048.	1.6	40
256	Salvage High Dose Rate Brachytherapy after Primary External Beam Irradiation in Localized Prostate Cancer: A Case Report. <i>Tumori</i> , 2009, 95, 553-556.	0.6	6
257	Comparison of fractionation schedules in the large heterogeneity limit. <i>Medical Physics</i> , 2009, 36, 1384-1388.	1.6	1
258	Positional Reproducibility and Effects of a Rectal Balloon in Prostate Cancer Radiotherapy. <i>Journal of Korean Medical Science</i> , 2009, 24, 894.	1.1	18
259	A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional conformal external-beam radiotherapy for localized prostate adenocarcinoma: A report on the first-year biochemical response. <i>Medicina (Lithuania)</i> , 2009, 45, 469.	0.8	15
261	Fitting techniques of cell survival curves in high-dose region for use in stereotactic body radiation therapy. <i>Physics in Medicine and Biology</i> , 2009, 54, 1593-1608.	1.6	41
262	Normal tissue complication probability: Does simultaneous integrated boost intensity-modulated radiotherapy score over other techniques in treatment of prostate adenocarcinoma. <i>Journal of Cancer Research and Therapeutics</i> , 2009, 5, 78.	0.3	4
263	Conventional radiotherapy or hypofractionation? A study of molecular changes resulting from different radiation fractionation schemes. <i>Cancer Biology and Therapy</i> , 2009, 8, 774-776.	1.5	3
264	A cone beam CT-guided online plan modification technique to correct interfractional anatomic changes for prostate cancer IMRT treatment. <i>Physics in Medicine and Biology</i> , 2009, 54, 1691-1703.	1.6	45
265	Encouraging early data for SBRT in prostate cancer. <i>Nature Reviews Urology</i> , 2009, 6, 478-479.	1.9	1
266	Proton radiation for localized prostate cancer. <i>Nature Reviews Urology</i> , 2009, 6, 324-330.	1.9	15

#	ARTICLE	IF	CITATIONS
267	Behind : In Response to Drs. Mavroidis and Lind. <i>Acta Oncol</i> gica, 2009, 48, 614-617.	0.8	0
268	Effect of edema associated with C131s prostate permanent seed implants on dosimetric quality indices. <i>Medical Physics</i> , 2009, 36, 3536-3542.	1.6	11
269	Dose Escalation Using a Hypofractionated, Intensity-Modulated Radiation Therapy Boost for Localized Prostate Cancer: Preliminary Results Addressing Concerns of High or Low $\alpha/\beta$ Ratio. <i>Clinical Genitourinary Cancer</i> , 2009, 7, E52-E57.	0.9	2
270	Current status and perspectives of brachytherapy for prostate cancer. <i>International Journal of Clinical Oncology</i> , 2009, 14, 31-36.	1.0	43
271	Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. <i>Brachytherapy</i> , 2009, 8, 45-51.	0.2	72
272	Phase II Study of Hypofractionated Simultaneous Integrated Boost With Tomotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 392-398.	0.4	58
273	Toxicity Assessment of Pelvic Intensity-Modulated Radiotherapy With Hypofractionated Simultaneous Integrated Boost to Prostate for Intermediate- and High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 413-420.	0.4	61
274	Radiation Dose Predicts for Biochemical Control in Intermediate-Risk Prostate Cancer Patients Treated With Low-Dose-Rate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 16-22.	0.4	60
275	A Soft Answer Turneth Away Wrath. Proverbs 15:1. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1333-1334.	0.4	4
276	Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials. <i>Clinical and Translational Oncology</i> , 2009, 11, 437-445.	1.2	30
277	Use of Gold Markers for Setup in Image-Guided Fractionated High-Dose-Rate Brachytherapy as a Monotherapy for Prostate Cancer. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 731-735.	1.0	12
278	Comment by J. SchÄfer, G. Welzel, F. Wenz on D. Norkus et al. A Randomized Trial Comparing Hypofractionated and Conventionally Fractionated Three-Dimensional External-Beam Radiotherapy for Localized Prostate Adenocarcinoma. A Report on Acute Toxicity. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 722-723.	1.0	2
279	Linear quadratic and tumour control probability modelling in external beam radiotherapy. <i>Journal of Mathematical Biology</i> , 2009, 58, 799-817.	0.8	78
280	Image guided dose escalated prostate radiotherapy: still room to improve. <i>Radiation Oncology</i> , 2009, 4, 50.	1.2	57
281	Clinical and Dosimetric Predictors of Acute Toxicity After a 4-Week Hypofractionated External Beam Radiotherapy Regimen for Prostate Cancer: Results From a Multicentric Prospective Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 39-45.	0.4	24
282	An Eight-Year Experience of HDR Brachytherapy Boost for Localized Prostate Cancer: Biopsy and PSA Outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 679-684.	0.4	77
283	Stereotactic Body Radiotherapy for Localized Prostate Cancer: Interim Results of a Prospective Phase II Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1043-1048.	0.4	305
284	On the impact of functional imaging accuracy on selective boosting IMRT. <i>Physica Medica</i> , 2009, 25, 12-24.	0.4	11



#	ARTICLE	IF	CITATIONS
285	Late Outcomes Following Hypofractionated Conformal Radiotherapy vs. Standard Fractionation for Localized Prostate Cancer: A Nonrandomized Contemporary Comparison. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1441-1446.	0.4	37
286	In Reply to Dr. Lee. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1332-1333.	0.4	4
287	Modeling of $\hat{I}\pm/\hat{I}^2$ for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 117.	3.5	77
288	Novel treatment methods for localized prostate cancer: hypofractionated robotic radiation therapy and adjuvant chemotherapy. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 953-962.	1.1	1
289	PSA response signatures â€“ a powerful new prognostic indicator after radiation for prostate cancer?. <i>Radiotherapy and Oncology</i> , 2009, 90, 382-388.	0.3	17
290	Endo-rectal balloon cavity dosimetry in a phantom: Performance under IMRT and helical tomotherapy beams. <i>Radiotherapy and Oncology</i> , 2009, 92, 48-56.	0.3	11
291	Doseâ€“volume effects for normal tissues in external radiotherapy: Pelvis. <i>Radiotherapy and Oncology</i> , 2009, 93, 153-167.	0.3	249
292	Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer. <i>Radiotherapy and Oncology</i> , 2009, 93, 234-240.	0.3	55
293	Dosimetric Comparison of Image Guidance by Megavoltage Computed Tomography versus Bone Alignment for Prostate Cancer Radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 241-247.	1.0	15
294	Life, Liberty, and the Pursuit of Protons: An Evidence-Based Review of the Role of Particle Therapy in the Treatment of Prostate Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2009, 15, 312-318.	1.0	24
295	Hypofractionation for Prostate Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2009, 15, 1-6.	1.0	67
296	Loss of radiobiological effect of imaging dose in image guided radiotherapy due to prolonged imaging-to-treatment times. <i>Medical Physics</i> , 2010, 37, 2761-2769.	1.6	6
297	Acute Toxicity in High-Risk Prostate Cancer Patients Treated With Androgen Suppression and Hypofractionated Intensity-Modulated Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 57-64.	0.4	51
298	Dose Gradient Near Targetâ€“Normal Structure Interface for Nonisocentric CyberKnife and Isocentric Intensity-Modulated Body Radiotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 58-63.	0.4	72
299	Stereotactic Body Radiotherapy for Primary Management of Early-Stage, Low- to Intermediate-Risk Prostate Cancer: Report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1297-1304.	0.4	55
300	Dosimetric and physical comparison of IMRT and CyberKnife plans in the treatment of localized prostate cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2010, 15, 181-189.	0.3	25
301	Cyberknife: A double edged sword?. <i>Reports of Practical Oncology and Radiotherapy</i> , 2010, 15, 93-97.	0.3	16
302	Generation of Composite Dose and Biological Effective Dose (BED) Over Multiple Treatment Modalities and Multistage Planning Using Deformable Image Registration. <i>Medical Dosimetry</i> , 2010, 35, 143-150.	0.4	20

#	ARTICLE	IF	CITATIONS
303	Long-Term Toxicity Following 3D Conformal Radiation Therapy for Prostate Cancer From the RTOG 9406 Phase I/II Dose Escalation Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 14-22.	0.4	101
304	Biologically Effective Dose (BED) Correlation With Biochemical Control After Low-Dose Rate Prostate Brachytherapy for Clinically Low-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 139-146.	0.4	15
305	Hypofractionation: What Does It Mean for Prostate Cancer Treatment?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 260-268.	0.4	26
306	Long-Term Outcome and Toxicity of Salvage Brachytherapy for Local Failure After Initial Radiotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1338-1344.	0.4	142
307	Phase II Trial of Combined High-Dose-Rate Brachytherapy and External Beam Radiotherapy for Adenocarcinoma of the Prostate: Preliminary Results of RTOG 0321. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 751-758.	0.4	111
308	Impact of Prolonged Fraction Delivery Times Simulating IMRT on Cultured Nasopharyngeal Carcinoma Cell Killing. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1541-1547.	0.4	27
309	Antagonistic interaction between bicalutamide, (Casodex®) and radiation in androgen-positive prostate cancer LNCaP cells. <i>Prostate</i> , 2010, 70, 401-411.	1.2	11
310	Late morbidity and oncological outcome after radical hypofractionated radiotherapy in men with prostate cancer. <i>BJU International</i> , 2010, 106, 1458-1462.	1.3	11
311	Radiotherapeutic Strategies in the Management of Low-Risk Prostate Cancer. <i>Scientific World Journal</i> , The, 2010, 10, 1854-1869.	0.8	10
312	CyberKnife Stereotactic Radiotherapy as Monotherapy for Low- to Intermediate-Stage Prostate Cancer: Early Experience, Feasibility, and Tolerance. <i>Journal of Endourology</i> , 2010, 24, 865-869.	1.1	48
313	External Beam Radiotherapy for Prostate Cancer. <i>Journal of Endourology</i> , 2010, 24, 781-789.	1.1	10
314	Dose Escalation Study with Two Different Hypofractionated Intensity Modulated Radiotherapy Techniques for Localized Prostate Cancer: Acute Toxicity. <i>Technology in Cancer Research and Treatment</i> , 2010, 9, 263-270.	0.8	4
315	Histopathologic Effects of Hypofractionated Robotic Radiation Therapy on Malignant and Benign Prostate Tissue. <i>Technology in Cancer Research and Treatment</i> , 2010, 9, 583-587.	0.8	8
316	21 years of Biologically Effective Dose. <i>British Journal of Radiology</i> , 2010, 83, 554-568.	1.0	474
317	Subjective and objective measures of late genitourinary morbidity following hypofractionated radiotherapy in men with prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2010, 13, 34-38.	2.0	6
318	Update on radiation-based therapies for prostate cancer. <i>Current Opinion in Oncology</i> , 2010, 22, 257-262.	1.1	13
319	<i>In vivo</i> real-time rectal wall dosimetry for prostate radiotherapy. <i>Physics in Medicine and Biology</i> , 2010, 55, 3859-3871.	1.6	51
320	Altered fractionation in radiotherapy: From radiobiological rationale to therapeutic gain. <i>Cancer Treatment Reviews</i> , 2010, 36, 606-614.	3.4	34

#	ARTICLE	IF	CITATIONS
321	The role of overall treatment time in the outcome of radiotherapy of prostate cancer: An analysis of biochemical failure in 4839 men treated between 1987 and 1995. <i>Radiotherapy and Oncology</i> , 2010, 96, 6-12.	0.3	95
322	Fractionation in prostate cancer – Is it time after all?. <i>Radiotherapy and Oncology</i> , 2010, 96, 1-5.	0.3	24
323	Which $\lambda/\lambda^2$ ratio and half-time of repair are useful for predicting outcomes in prostate cancer?. <i>Radiotherapy and Oncology</i> , 2010, 97, 462-466.	0.3	26
324	Analytical investigation of the possibility of parameter invariant TCP-based radiation therapy plan ranking. <i>Acta Oncologica</i> , 2010, 49, 1324-1333.	0.8	12
325	A method to separate the rectum from the prostate during proton beam radiotherapy of prostate cancer patients. <i>Acta Oncologica</i> , 2010, 49, 500-505.	0.8	26
326	When tumor repopulation starts? The onset time of prostate cancer during radiation therapy. <i>Acta Oncologica</i> , 2010, 49, 1269-1275.	0.8	25
327	Stereotactic Body Radiotherapy for Prostate Cancer: Current Results of a Phase II Trial. <i>Frontiers of Radiation Therapy and Oncology</i> , 2011, 43, 428-437.	1.4	15
328	Prostate. <i>Medical Radiology</i> , 2011, , 949-1025.	0.0	0
329	Radiobiological rationale and clinical implications of hypofractionated radiation therapy. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2011, 15, 221-229.	0.6	22
330	Stereotactic body radiation therapy for prostate cancer. <i>Future Oncology</i> , 2011, 7, 1077-1086.	1.1	9
331	Long-term biochemical control of prostate cancer after standard or hyper-fractionation: Evidence for different outcomes between low-intermediate and high risk patients. <i>Radiotherapy and Oncology</i> , 2011, 101, 454-459.	0.3	13
332	Twice-Weekly Hypofractionated Intensity-Modulated Radiotherapy for Localized Prostate Cancer With Low-Risk Nodal Involvement: Toxicity and Outcome From a Dose Escalation Pilot Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 382-389.	0.4	23
333	The Omega on Alpha and Beta. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 319-320.	0.4	22
334	Role of Principal Component Analysis in Predicting Toxicity in Prostate Cancer Patients Treated With Hypofractionated Intensity-Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e415-e421.	0.4	25
335	Image-Guided Stereotactic Body Radiation Therapy for Localized Prostate Cancer. <i>Tumori</i> , 2011, 97, 43-48.	0.6	71
336	Molecular Targets for Radiation Oncology in Prostate Cancer. <i>Frontiers in Oncology</i> , 2011, 1, 17.	1.3	12
337	Stereotactic Body Radiation Therapy for Low- and Low-Intermediate-Risk Prostate Cancer: Is there a Dose Effect?. <i>Frontiers in Oncology</i> , 2011, 1, 49.	1.3	20
338	Practical Time-Dose Evaluations, or How to Stop Worrying and Learn to Love Linear Quadratics. <i>Medical Radiology</i> , 2011, , 3-50.	0.0	4

#	ARTICLE	IF	CITATIONS
339	Stereotactic body radiation therapy: an emerging technique for prostate cancer treatment. Radiographer, 2011, 58, 25-29.	0.1	0
340	Advances in Treatment Techniques. Cancer Journal (Sudbury, Mass ), 2011, 17, 177-181.	1.0	27
341	Confirmation of a Low $\hat{\alpha}/\hat{\beta}^2$ Ratio for Prostate Cancer Treated by External Beam Radiation Therapy Alone Using a Post-Treatment Repeated-Measures Model for PSA Dynamics. International Journal of Radiation Oncology Biology Physics, 2011, 79, 195-201.	0.4	131
342	Urethral toxicity vs. cancer control—Lessons to be learned from high-dose rate brachytherapy combined with intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. Brachytherapy, 2011, 10, 286-294.	0.2	13
343	Internal radiotherapy techniques using radiolanthanide praseodymium-142: a review of production routes, brachytherapy, unsealed source therapy. Annals of Nuclear Medicine, 2011, 25, 529-535.	1.2	30
344	Intelligent ePR system for evidence-based research in radiotherapy: proton therapy for prostate cancer. International Journal of Computer Assisted Radiology and Surgery, 2011, 6, 769-784.	1.7	6
345	Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen <math>\leq 1.0</math> ng/ml. Radiation Oncology, 2011, 6, 150.	1.2	10
346	Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiation Oncology, 2011, 6, 3.	1.2	200
347	Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer, 2011, 117, 2629-2636.	2.0	67
348	Acute and Late Toxicity in a Randomized Trial of Conventional Versus Hypofractionated Three-Dimensional Conformal Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1013-1021.	0.4	145
349	Deriving Prostate Alpha-Beta Ratio Using Carefully Matched Groups, Long Follow-Up and the Phoenix Definition of Biochemical Failure. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1029-1036.	0.4	24
350	Monotherapeutic High-Dose-Rate Brachytherapy for Prostate Cancer: Five-Year Results of an Extreme Hypofractionation Regimen With 54 Gy in Nine Fractions. International Journal of Radiation Oncology Biology Physics, 2011, 80, 469-475.	0.4	102
351	A Phase II Trial of Arc-Based Hypofractionated Intensity-Modulated Radiotherapy in Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1306-1315.	0.4	37
352	Hypofractionation Results in Reduced Tumor Cell Kill Compared to Conventional Fractionation for Tumors With Regions of Hypoxia. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1188-1195.	0.4	148
353	Moving Toward Focal Therapy in Prostate Cancer: Dual-Isotope Permanent Seed Implants as a Possible Solution. International Journal of Radiation Oncology Biology Physics, 2011, 81, 297-304.	0.4	15
354	Postprostatectomy radiation therapy: an evidence-based review. Future Oncology, 2011, 7, 1429-1440.	1.1	12
355	Stereotactic Body Radiotherapy. Medical Radiology, 2011, , 363-400.	0.0	0
356	Phase I Dose-Escalation Study of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 2020-2026.	0.8	234

#	ARTICLE	IF	CITATIONS
357	The impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancers. <i>Physics in Medicine and Biology</i> , 2011, 56, 4895-4912.	1.6	2
358	Acute Toxicity After CyberKnife-Delivered Hypofractionated Radiotherapy for Treatment of Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 6-10.	0.6	35
359	Shaped Beam Radiosurgery. , 2011, , .		0
360	Feasibility of safe ultra-high (EQD <sub>2</sub> >100 Gy) dose escalation on dominant intra-prostatic lesions (DILs) by Helical Tomotherapy. <i>Acta Oncologica</i> , 2011, 50, 25-34.	0.8	42
361	Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy: An Emerging Initial Radiation Treatment Option for Organ-Confined Prostate Cancer. <i>Journal of Oncology Practice</i> , 2012, 8, e31s-e37s.	2.5	78
362	Helical tomotherapy provides efficacy similar to that of intensity-modulated radiation therapy with dosimetric benefits for endometrial carcinoma. <i>OncoTargets and Therapy</i> , 2012, 5, 245.	1.0	7
363	Quality-of-Life Outcomes in High-Risk Prostate Cancer Patients Treated with Helical Tomotherapy in a Hypofractionated Radiation Schedule with Long-Term Androgen Suppression. <i>Current Oncology</i> , 2012, 19, 201-210.	0.9	6
364	The effect of 6 and 15 MV on intensity-modulated radiation therapy prostate cancer treatment: plan evaluation, tumour control probability and normal tissue complication probability analysis, and the theoretical risk of secondary induced malignancies. <i>British Journal of Radiology</i> , 2012, 85, 423-432.	1.0	22
365	Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients. <i>Acta Oncologica</i> , 2012, 51, 963-974.	0.8	182
366	Hypofractionated radiotherapy in prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 965-972.	1.1	3
367	Image-guided radiotherapy: from current concept to future perspectives. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 688-699.	12.5	379
368	The use and QA of biologically related models for treatment planning: Short report of the TG-166 of the therapy physics committee of the AAPM. <i>Medical Physics</i> , 2012, 39, 1386-1409.	1.6	203
369	Hypofractionated Proton Boost Combined with External Beam Radiotherapy for Treatment of Localized Prostate Cancer. <i>Prostate Cancer</i> , 2012, 2012, 1-14.	0.4	34
370	Hypofractionated helical intensity-modulated radiotherapy (75 Gy at 2.5 Gy/fraction) for intermediate- and high-risk prostate cancer: Assessment of toxicity. <i>Journal of Radiotherapy in Practice</i> , 2012, 11, 145-154.	0.2	1
371	Dosimetric and deformation effects of image-guided interventions during stereotactic body radiation therapy of the prostate using an endorectal balloon. <i>Medical Physics</i> , 2012, 39, 3080-3088.	1.6	18
372	What do we know about the $\hat{\mu}/\hat{\sigma}^2$ for prostate cancer?. <i>Medical Physics</i> , 2012, 39, 3189-3201.	1.6	32
373	Biological effect of dose distortion by fiducial markers in spot-scanning proton therapy with a limited number of fields: A simulation study. <i>Medical Physics</i> , 2012, 39, 5584-5591.	1.6	26
374	Hypofractionated radiotherapy for prostate cancer. <i>Lancet Oncology</i> , The, 2012, 13, 5-6.	5.1	6

#	ARTICLE	IF	CITATIONS
375	Hypofractionated Concomitant Intensity-Modulated Radiotherapy Boost for High-Risk Prostate Cancer: Late Toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 898-905.	0.4	46
376	Later Outcomes and Alpha/Beta Estimate From Hypofractionated Conformal Three-Dimensional Radiotherapy Versus Standard Fractionation for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1200-1207.	0.4	67
377	Rectal Bleeding After High-Dose-Rate Brachytherapy Combined With Hypofractionated External-Beam Radiotherapy for Localized Prostate Cancer: The Relationship Between Dose-Volume Histogram Parameters and the Occurrence Rate. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e211-e217.	0.4	12
378	High-Dose-Rate Brachytherapy as Monotherapy Delivered in Two Fractions Within One Day for Favorable/Intermediate-Risk Prostate Cancer: Preliminary Toxicity Data. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 927-932.	0.4	84
379	Single-Fraction High-Dose-Rate Brachytherapy and Hypofractionated External Beam Radiation Therapy in the Treatment of Intermediate-Risk Prostate Cancer – Long Term Results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1417-1423.	0.4	18
380	Quality of Life After Hypofractionated Concomitant Intensity-Modulated Radiotherapy Boost for High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 617-623.	0.4	14
381	We Forget at Our Peril the Lessons Built into the $\hat{\mu}/\hat{\sigma}^2$ Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1312-1314.	0.4	23
382	In Reply to Yeoh et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 4.	0.4	1
383	Updated Results and Patterns of Failure in a Randomized Hypofractionation Trial for High-risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 1172-1178.	0.4	187
384	The Power of Radiation Biophysics – Let's Use It. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 309-311.	0.4	26
385	In Reply to Ohri et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 4-5.	0.4	1
386	Exploring Two Two-Edged Swords. <i>Radiation Research</i> , 2012, 178, 7-16.	0.7	12
387	Phase I/II trial of single-fraction high-dose-rate brachytherapy – boosted hypofractionated intensity-modulated radiation therapy for localized adenocarcinoma of the prostate. <i>Brachytherapy</i> , 2012, 11, 292-298.	0.2	12
388	Stereotactic Body Radiation Therapy (SBRT) for Clinically Localized Prostate Cancer: Endoscopic Outcomes, Rectal Toxicity, and Quality of Life. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S647.	0.4	0
389	Phase II study of hypofractionated image-guided radiotherapy for localized prostate cancer: Outcomes of 55Gy in 16 fractions at 3.4Gy per fraction. <i>Radiotherapy and Oncology</i> , 2012, 103, 210-216.	0.3	19
390	Salvage radiotherapy for prostate cancer. <i>Cancer Biology and Therapy</i> , 2012, 13, 1449-1453.	1.5	1
391	Intra-fraction Motion during Extreme Hypofractionated Radiotherapy of the Prostate using Pre- and Post-treatment Imaging. <i>Clinical Oncology</i> , 2012, 24, 640-645.	0.6	28
392	Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 101-108.	2.0	44

#	ARTICLE	IF	CITATIONS
394	On the beam direction search space in computerized non-coplanar beam angle optimization for IMRT prostate SBRT. <i>Physics in Medicine and Biology</i> , 2012, 57, 5441-5458.	1.6	56
396	Intraoperative Radiation Therapy. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2012, 22, 269-279.	0.4	1
397	Carbon ion radiation therapy for prostate cancer. <i>International Journal of Urology</i> , 2012, 19, 296-305.	0.5	76
398	Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. <i>Radiation Oncology</i> , 2013, 8, 118.	1.2	172
399	High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients. <i>Radiation Oncology</i> , 2013, 8, 115.	1.2	29
400	Acute toxicity profile in prostate cancer with conventional and hypofractionated treatment. <i>Radiation Oncology</i> , 2013, 8, 94.	1.2	11
401	Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. <i>Journal of Radiation Oncology</i> , 2013, 2, 63-70.	0.7	70
402	Loss of local control due to tumor displacement as a function of margin size, dose response slope, and number of fractions. <i>Medical Physics</i> , 2013, 40, 041715.	1.6	10
403	A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer. <i>Brachytherapy</i> , 2013, 12, 428-433.	0.2	45
404	Prostate Brachytherapy Implantation Treatment Techniques. , 2013, , 87-101.		0
405	Prognostic factors for acute toxicity in prostate cancer patients treated with high-dose hypofractionated radiotherapy. <i>Clinical and Translational Oncology</i> , 2013, 15, 643-651.	1.2	4
406	Optimal solution for a cancer radiotherapy problem. <i>Journal of Mathematical Biology</i> , 2013, 66, 311-349.	0.8	28
408	Wartości dawek w gruczole krokowym i narządach krytycznych w odmiennych schematach brachyterapii HDR. <i>Zeszyty Naukowe WCO Letters in Oncology Science</i> , 2013, 10, 35-53.	0.2	0
409	Maximizing the biological effect of proton dose delivered with scanned beams via inhomogeneous daily dose distributions. <i>Medical Physics</i> , 2013, 40, 051708.	1.6	13
410	A TCP model for external beam treatment of intermediate risk prostate cancer. <i>Medical Physics</i> , 2013, 40, 031709.	1.6	20
412	Biological Dose Escalation and Hypofractionation: What is There to be Gained and How Will it Best be Done?. <i>Clinical Oncology</i> , 2013, 25, 483-498.	0.6	35
414	Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer. <i>Radiation Oncology</i> , 2013, 8, 197.	1.2	8
415	Meta-analysis of the Alpha/Beta Ratio for Prostate Cancer in the Presence of an Overall Time Factor: Bad News, Good News, or No News?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 89-94.	0.4	179

#	ARTICLE	IF	CITATIONS
416	Early quality of life outcomes in patients with prostate cancer managed by high-dose-rate brachytherapy as monotherapy. <i>International Journal of Urology</i> , 2013, 20, 185-192.	0.5	19
417	CyberKnife – przyszłość w leczeniu raka stercza?. <i>Zeszyty Naukowe WCO Letters in Oncology Science</i> , 2013, 10, 83-87.	0.2	0
418	Contemporary Issues in Radiotherapy for Clinically Localized Prostate Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1137-1162.	0.9	4
420	Estimation of a Self-Consistent Set of Radiobiological Parameters From Hypofractionated Versus Standard Radiation Therapy of Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, e231-e237.	0.4	38
421	Whole-Pelvic Nodal Radiation Therapy in the Context of Hypofractionation for High-Risk Prostate Cancer Patients: A Step Forward. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 600-605.	0.4	38
422	Prostate Hypofractionated Radiation Therapy: Injection of Hyaluronic Acid to Better Preserve The Rectal Wall. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 72-76.	0.4	21
423	Analysis of high-dose rate brachytherapy dose distribution resemblance in CyberKnife hypofractionated treatment plans of localized prostate cancer. <i>Medical Dosimetry</i> , 2013, 38, 385-389.	0.4	16
424	A phase II study of hypofractionated proton therapy for prostate cancer. <i>Acta Oncologica</i> , 2013, 52, 477-485.	0.8	30
425	Effect of radiation protraction on BED in the case of large fraction dose. <i>Medical Physics</i> , 2013, 40, 081716.	1.6	1
426	In situ Tumor Ablation with Radiation Therapy: Its Effect on the Tumor Microenvironment and Anti-tumor Immunity. , 2013, , 109-119.		3
427	Hypofractionated External-Beam Radiotherapy for Prostate Cancer. <i>Prostate Cancer</i> , 2013, 2013, 1-11.	0.4	12
428	Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression. <i>Acta Oncologica</i> , 2013, 52, 492-497.	0.8	13
429	Prostate Cancer and the Hypofractionation Hypothesis. <i>Journal of Clinical Oncology</i> , 2013, 31, 3849-3851.	0.8	28
430	The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer. <i>Journal of Radiation Research</i> , 2013, 54, 781-788.	0.8	36
431	Utilitarian prioritization of radiation oncology patients based on maximization of population tumour control. <i>Physics in Medicine and Biology</i> , 2013, 58, 4013-4029.	1.6	5
432	Interstitial Prostate Brachytherapy. , 2013, , .		1
433	Clinical consequences of relative biological effectiveness variations in proton radiotherapy of the prostate, brain and liver. <i>Physics in Medicine and Biology</i> , 2013, 58, 2103-2117.	1.6	84
434	Transformation of Physical DVHs to Radiobiologically Equivalent Ones in Hypofractionated Radiotherapy Analyzing Dosimetric and Clinical Parameters: A Practical Approach for Routine Clinical Practice in Radiation Oncology. <i>Computational and Mathematical Methods in Medicine</i> , 2013, 2013, 1-8.	0.7	4



#	ARTICLE	IF	CITATIONS
435	Hypofractionated Intensity-Modulated Simultaneous Integrated Boost and Image-Guided Radiotherapy in the Treatment of High-Risk Prostate Cancer Patients: A Preliminary Report on Acute Toxicity. <i>Tumori</i> , 2013, 99, 474-479.	0.6	3
437	Decreasing the Dose to the Rectal Wall by Using a Rectal Retractor during Radiotherapy of Prostate Cancer: A Comparative Treatment Planning Study. <i>Journal of Radiotherapy</i> , 2014, 2014, 1-7.	0.2	5
438	Hypofractionation in Prostate Cancer: Radiobiological Basis and Clinical Appliace. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	17
439	Hypofractionated helical tomotherapy (75 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term analysis of gastrointestinal and genitourinary toxicity. <i>OncoTargets and Therapy</i> , 2014, 7, 553.	1.0	5
441	Proctitis following stereotactic body radiation therapy for prostate cancer. <i>Radiation Oncology</i> , 2014, 9, 277.	1.2	26
442	Dosimetric analysis of urethral strictures following HDR 192Ir brachytherapy as monotherapy for intermediate- and high-risk prostate cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 410-413.	0.3	15
443	Quality of Life and Sexual Health in the Aging of PCa Survivors. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-16.	0.6	13
444	Low Temperature Plasma: A Novel Focal Therapy for Localized Prostate Cancer?. <i>BioMed Research International</i> , 2014, 2014, 1-15.	0.9	41
445	The Early Result of Whole Pelvic Radiotherapy and Stereotactic Body Radiotherapy Boost for High-Risk Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 278.	1.3	34
446	Stereotactic Body Radiation Therapy for Prostate Cancer Patients with Old Age or Medical Comorbidity. <i>Medicine (United States)</i> , 2014, 93, e290.	0.4	23
447	High-Dose-Rate Brachytherapy in the Treatment of Clinically Localized Prostate Cancer. <i>Medical Radiology</i> , 2014, , 211-224.	0.0	0
448	Determination of prescription dose for Cs-131 permanent implants using the BED formalism including resensitization correction. <i>Medical Physics</i> , 2014, 41, 024101.	1.6	4
449	Stereotactic body radiotherapy for primary prostate cancer: A systematic review. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 601-611.	0.9	25
450	High-dose-rate brachytherapy as monotherapy for prostate cancer. <i>Brachytherapy</i> , 2014, 13, 529-541.	0.2	82
451	Prostatic displacement during extreme hypofractionated radiotherapy using volumetric modulated arc therapy (VMAT). <i>Radiation Oncology</i> , 2014, 9, 262.	1.2	16
452	Hypofractionated radiotherapy for prostate cancer. <i>Radiation Oncology</i> , 2014, 9, 275.	1.2	56
453	Treatment planning comparison between high dose rate and intensity-modulated radiation therapy for prostate cancer as a means of boost dose. <i>Journal of Radiotherapy in Practice</i> , 2014, 13, 332-339.	0.2	1
454	ACR Appropriateness Criteria® Definitive External-Beam Irradiation in Stage T1 and T2 Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 278-288.	0.6	13

#	ARTICLE	IF	CITATIONS
455	High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective. <i>Journal of Contemporary Brachytherapy</i> , 2014, 1, 91-98.	0.4	33
456	A Phase II Trial of Stereotactic Ablative Body Radiotherapy for Low-Risk Prostate Cancer Using a Non-Robotic Linear Accelerator and Real-Time Target Tracking: Report of Toxicity, Quality of Life, and Disease Control Outcomes with 5-Year Minimum Follow-Up. <i>Frontiers in Oncology</i> , 2014, 4, 279.	1.3	62
457	Stereotactic body radiotherapy for prostate cancer: A preliminary report. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, e46-53.	0.7	16
458	Initial experience with stereotactic body radiation therapy for localized prostate cancer using helical tomotherapy. <i>Clinical and Translational Oncology</i> , 2014, 16, 380-385.	1.2	13
459	Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. <i>Radiation Oncology</i> , 2014, 9, 42.	1.2	50
460	The influence of the local effect model parameters on the prediction of the tumor control probability for prostate cancer. <i>Physics in Medicine and Biology</i> , 2014, 59, 3019-3040.	1.6	9
461	On the Sensitivity of $\hat{I}_{\pm}/\hat{I}^2$ Prediction to Dose Calculation Methodology in Prostate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 345-350.	0.4	6
462	Monotherapeutic high-dose-rate brachytherapy for prostate cancer: A dose reduction trial. <i>Radiotherapy and Oncology</i> , 2014, 110, 114-119.	0.3	16
463	Practical aspects and uncertainty analysis of biological effective dose (BED) regarding its three-dimensional calculation in multiphase radiotherapy treatment plans. <i>Medical Physics</i> , 2014, 41, 071707.	1.6	4
464	Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: Who, when, where and how?. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2014, 18, 524-534.	0.6	47
465	Early closure of phase II prospective study on acute and late tolerance of hypofractionated radiotherapy in low-risk prostate cancer patients. <i>Reports of Practical Oncology and Radiotherapy</i> , 2014, 19, 337-342.	0.3	6
466	Biologically effective dose and definitive radiation treatment for localized prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 732-738.	1.0	9
467	Early results of urethral dose reduction and small safety margin in intensity-modulated radiation therapy (IMRT) for localized prostate cancer using a real-time tumor-tracking radiotherapy (RTRT) system. <i>Radiation Oncology</i> , 2014, 9, 118.	1.2	22
468	ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2014, 13, 27-31.	0.2	24
469	The Tumor Radiobiology of SRS and SBRT: Are More Than the 5 Rs Involved?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 254-262.	0.4	462
470	Oncology Scanâ€™Rising Stars, Fading Stars, and Shooting Stars: New Trends in Prostate Cancer Management. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 4-6.	0.4	4
471	Is Biochemical Relapse-free Survival After Profoundly Hypofractionated Radiotherapy Consistent with Current Radiobiological Models?. <i>Clinical Oncology</i> , 2014, 26, 216-229.	0.6	28
472	Risk of Late Toxicity in Men Receiving Dose-Escalated Hypofractionated Intensity Modulated Prostate Radiation Therapy: Results From a Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1074-1084.	0.4	127

#	ARTICLE	IF	CITATIONS
473	Treatment plan comparison between stereotactic body radiation therapy techniques for prostate cancer: Non-isocentric CyberKnife versus isocentric RapidArc. <i>Physica Medica</i> , 2014, 30, 654-661.	0.4	34
474	Hypo-fractionation in Prostate Cancer: Biological Aspects. <i>Medical Radiology</i> , 2014, , 155-162.	0.0	0
475	A phenomenological relative biological effectiveness (RBE) model for proton therapy based on all published<i>in vitro</i> cell survival data. <i>Physics in Medicine and Biology</i> , 2015, 60, 8399-8416.	1.6	246
476	Altered radiation fractionation schedules for clinically localised and locally advanced prostate cancer. <i>The Cochrane Library</i> , 0, , .	1.5	3
477	Comparison of VMAT&SABR treatment plans with flattening filter (FF) and flattening filter&free (FFF) beam for localized prostate cancer. <i>Journal of Applied Clinical Medical Physics</i> , 2015, 16, 302-313.	0.8	18
478	Minimizing metastatic risk in radiotherapy fractionation schedules. <i>Physics in Medicine and Biology</i> , 2015, 60, N405-N417.	1.6	4
479	Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR). <i>Radiation Oncology</i> , 2015, 10, 122.	1.2	36
480	Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma. <i>Journal of Korean Medical Science</i> , 2015, 30, 710.	1.1	8
481	Non-melanoma skin cancer treated with high-dose-rate brachytherapy and Valencia applicator in elderly patients: a retrospective case series. <i>Journal of Contemporary Brachytherapy</i> , 2015, 6, 437-444.	0.4	42
482	Genomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate Cancer. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	11
483	Optimal weekly scheduling in fractionated radiotherapy: effect of an upper bound on the dose fraction size. <i>Journal of Mathematical Biology</i> , 2015, 71, 361-398.	0.8	6
484	Stereotactic ablative radiation therapy with volumetric modulated arc therapy in flattening filter-free mode for low-, intermediate-, and high-risk prostate cancer patients: Are 2 arcs better than 1?. <i>Practical Radiation Oncology</i> , 2015, 5, e489-e497.	1.1	5
485	High-dose and fractionation effects in stereotactic radiation therapy: Analysis of tumor control data from 2965 patients. <i>Radiotherapy and Oncology</i> , 2015, 115, 327-334.	0.3	110
486	Dose-Escalated Robotic SBRT for Stage I&II Prostate Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 48.	1.3	22
487	Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer. <i>Brachytherapy</i> , 2015, 14, 795-800.	0.2	12
488	Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer. <i>Prostate International</i> , 2015, 3, 118-122.	1.2	8
490	Continuous Monitoring and Intrafraction Target Position Correction During Treatment Improves Target Coverage for Patients Undergoing SBRT Prostate Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 588-594.	0.4	67
491	Prostate-specific antigen kinetics after primary stereotactic body radiation therapy using CyberKnife for localized prostate cancer. <i>Prostate International</i> , 2015, 3, 6-9.	1.2	13

#	ARTICLE	IF	CITATIONS
492	Stereotactic Body Radiotherapy. , 2015, , .		3
493	[11C]-Choline PET/CT-guided simultaneous integrated boost to dominant intraprostatic lesions using intensity-modulated radiation therapy with helical tomotherapy technique for dose escalation. Journal of Radiation Oncology, 2015, 4, 87-93.	0.7	0
494	A Phase 1/2 Trial of Brief Androgen Suppression and Stereotactic Radiation Therapy (FASTR) for High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 856-862.	0.4	63
495	Noncoplanar Beam Angle Class Solutions to Replace Time-Consuming Patient-Specific Beam Angle Optimization in Robotic Prostate Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 762-770.	0.4	16
496	Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction. Future Oncology, 2015, 11, 819-831.	1.1	11
497	Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer. Radiation Oncology, 2015, 10, 95.	1.2	4
498	Prostate Hypofractionated Radiation Therapy With Injection of Hyaluronic Acid: Acute Toxicities in a Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2015, 91, 730-736.	0.4	30
499	Will intrafraction repair have negative consequences on extreme hypofractionation in prostate radiation therapy?. British Journal of Radiology, 2015, 88, 20150588.	1.0	11
501	Hypofractionated radiation therapy for prostate cancer: The McGill University Health Center experience. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2015, 19, 431-436.	0.6	7
502	Radiotherapy in Prostate Cancer. Medical Radiology, 2015, , .	0.0	6
503	Stereotactic body radiation therapy for prostate cancer: Rational and reasonable. Practical Radiation Oncology, 2015, 5, 188-192.	1.1	11
504	Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer. World Journal of Urology, 2015, 33, 1197-1203.	1.2	35
506	The effect of rectal retractor on intrafraction motion of the prostate. Biomedical Physics and Engineering Express, 2016, 2, 035021.	0.6	11
507	Rationale and Protocol of AIRC IG-13218, Short-Term Radiotherapy for Early Prostate Cancer with Concomitant Boost to the Dominant Lesion. Tumori, 2016, 102, 536-540.	0.6	15
508	Advances in Radiotherapy for Prostate Cancer Treatment. Prostate Cancer, 2016, 2016, 1-2.	0.4	1
509	Systematic Review of Focal Prostate Brachytherapy and the Future Implementation of Image-Guided Prostate HDR Brachytherapy Using MR-Ultrasound Fusion. Prostate Cancer, 2016, 2016, 1-13.	0.4	28
510	Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature. Journal of Contemporary Brachytherapy, 2016, 6, 533-540.	0.4	56
511	The Role of Hypofractionated Radiation Therapy with Photons, Protons, and Heavy Ions for Treating Extracranial Lesions. Frontiers in Oncology, 2015, 5, 302.	1.3	20

#	ARTICLE	IF	CITATIONS
512	Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience. <i>Frontiers in Oncology</i> , 2016, 6, 114.	1.3	28
513	Big Data Analytics for Prostate Radiotherapy. <i>Frontiers in Oncology</i> , 2016, 6, 149.	1.3	34
514	Making Radiation Therapy for Prostate Cancer More Economical and More Convenient. <i>Journal of Clinical Oncology</i> , 2016, 34, 2323-2324.	0.8	20
515	Advantages of Binomial Likelihood Maximization for Analyzing and Modeling Cell Survival Curves. <i>Radiation Research</i> , 2016, 185, 246-256.	0.7	9
516	Exploiting Gene Expression Kinetics in Conventional Radiotherapy, Hyperfractionation, and Hypofractionation for Targeted Therapy. <i>Seminars in Radiation Oncology</i> , 2016, 26, 254-260.	1.0	5
517	Assessment of radiobiological metrics applied to patient-specific QA process of VMAT prostate treatments. <i>Journal of Applied Clinical Medical Physics</i> , 2016, 17, 341-367.	0.8	17
518	Trends in targeted prostate brachytherapy: from multiparametric MRI to nanomolecular radiosensitizers. <i>Cancer Nanotechnology</i> , 2016, 7, 6.	1.9	9
519	A validated tumor control probability model based on a meta-analysis of low, intermediate, and high-risk prostate cancer patients treated by photon, proton, or carbon ion radiotherapy. <i>Medical Physics</i> , 2016, 43, 734-747.	1.6	17
520	Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase II Study. <i>Clinical Oncology</i> , 2016, 28, 490-500.	0.6	21
521	Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer. <i>Radiotherapy and Oncology</i> , 2016, 118, 99-104.	0.3	8
522	Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy for low- and intermediate-risk prostate cancer. <i>Cancer Treatment Communications</i> , 2016, 5, 46-50.	0.4	1
523	Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer. <i>Prostate International</i> , 2016, 4, 25-29.	1.2	5
524	Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2325-2332.	0.8	490
525	SBRT for prostate cancer: Challenges and features from a physicist prospective. <i>Physica Medica</i> , 2016, 32, 479-484.	0.4	23
527	Alpha/beta ( $\alpha/\beta$ ) ratio for prostate cancer derived from external beam radiotherapy and brachytherapy boost. <i>British Journal of Radiology</i> , 2016, 89, 20150957.	1.0	12
528	Fit Patient with Nonmetastatic Castration-resistant Prostate Cancer, Lower Urinary Tract Symptoms, and Severe Recurrent Haematuria. <i>European Urology Focus</i> , 2016, 2, 477-478.	1.6	0
529	Sexual Function After Hypofractionated Versus Conventionally Fractionated Radiotherapy for Prostate Cancer: Results from the Randomized Phase III HYPRO Trial. <i>Journal of Sexual Medicine</i> , 2016, 13, 1695-1703.	0.3	8
530	Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low- and intermediate-risk prostate cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 388-395.	0.7	8

#	ARTICLE	IF	CITATIONS
531	Extreme hypofractionation for early prostate cancer: Biology meets technology. <i>Cancer Treatment Reviews</i> , 2016, 50, 48-60.	3.4	40
532	Hypofractionated image guided radiation therapy followed by prostate seed implant boost for men with newly diagnosed intermediate and high risk adenocarcinoma of the prostate: Preliminary results of a phase 2 prospective study. <i>Advances in Radiation Oncology</i> , 2016, 1, 317-324.	0.6	0
533	Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 121, 113-117.	0.3	15
534	A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients. <i>Radiotherapy and Oncology</i> , 2016, 121, 299-303.	0.3	20
535	Stereotactic Body Radiation Therapy for Localized Prostate Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 307-313.	1.0	16
536	Radiation Therapy in Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 327-328.	0.6	0
538	Focal or whole-gland salvage prostate brachytherapy with iodine seeds with or without a rectal spacer for postradiotherapy local failure: How best to spare the rectum?. <i>Brachytherapy</i> , 2016, 15, 406-411.	0.2	14
539	The Outcome for Patients With Pathologic Node-Positive Prostate Cancer Treated With Intensity Modulated Radiation Therapy and Androgen Deprivation Therapy: A Case-Matched Analysis of pN1 and pN0 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 323-332.	0.4	19
540	Hypofractionation for prostate cancer: tested and proven. <i>Lancet Oncology</i> , The, 2016, 17, 1020-1022.	5.1	10
541	Applying radiobiological plan ranking methodology to VMAT prostate SBRT. <i>Physica Medica</i> , 2016, 32, 636-641.	0.4	8
542	Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer. <i>Radiation Oncology</i> , 2016, 11, 8.	1.2	38
543	Hypofractionated Helical Tomotherapy for Older Aged Patients With Prostate Cancer. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 546-554.	0.8	6
544	A tumour control probability model for radiotherapy of prostate cancer using magnetic resonance imaging-based apparent diffusion coefficient maps. <i>Radiotherapy and Oncology</i> , 2016, 119, 111-116.	0.3	26
545	Can We Advance Proton Therapy for Prostate? Considering Alternative Beam Angles and Relative Biological Effectiveness Variations When Comparing Against Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 454-464.	0.4	46
546	High-Dose-Rate Brachytherapy as Monotherapy for Intermediate- and High-Risk Prostate Cancer: Clinical Results for a Median 8-Year Follow-Up. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 675-682.	0.4	72
547	Impact of the use of an endorectal balloon on rectal dosimetry during stereotactic body radiation therapy for localized prostate cancer. <i>Practical Radiation Oncology</i> , 2016, 6, 262-267.	1.1	13
549	Optimal fractionation in radiotherapy with multiple normal tissues. <i>Mathematical Medicine and Biology</i> , 2016, 33, 211-252.	0.8	29
550	Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 21-27.	0.7	10

#	ARTICLE	IF	CITATIONS
551	Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e342-e347.	0.7	14
552	Inclusion of a variable $\langle \text{scp} \rangle \text{RBE} \langle / \text{scp} \rangle$ into proton and photon plan comparison for various fractionation schedules in prostate radiation therapy. <i>Medical Physics</i> , 2017, 44, 810-822.	1.6	49
553	Nationwide, Multicenter, Retrospective Study on High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 952-961.	0.4	15
554	Acute toxicity and its dosimetric correlates for high-risk prostate cancer treated with moderately hypofractionated radiotherapy. <i>Medical Dosimetry</i> , 2017, 42, 18-23.	0.4	12
555	A phenomenological relative biological effectiveness approach for proton therapy based on an improved description of the mixed radiation field. <i>Physics in Medicine and Biology</i> , 2017, 62, 1378-1395.	1.6	42
556	Radiotherapy in the Management of Prostate Cancer. <i>Medical Radiology</i> , 2017, , 87-112.	0.0	0
557	Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium. <i>Brachytherapy</i> , 2017, 16, 503-510.	0.2	31
558	Dosimetric and radiobiological comparison of Cyberknife and Tomotherapy in stereotactic body radiotherapy for localized prostate cancer. <i>Journal of X-Ray Science and Technology</i> , 2017, 25, 465-477.	0.7	5
559	Hypofractionated stereotactic body radiotherapy for localized prostate cancer – first Nordic clinical experience. <i>Acta Oncologica</i> , 2017, 56, 978-983.	0.8	26
560	Dosimetric impacts of endorectal balloon in CyberKnife stereotactic body radiation therapy ( $\langle \text{scp} \rangle \text{SBRT} \langle / \text{scp} \rangle$ ) for early-stage prostate cancer. <i>Journal of Applied Clinical Medical Physics</i> , 2017, 18, 37-43.	0.8	7
561	Incorporation of relative biological effectiveness uncertainties into proton plan robustness evaluation. <i>Acta Oncologica</i> , 2017, 56, 769-778.	0.8	35
562	Hypofractionation for prostate cancer: an update. <i>Expert Review of Endocrinology and Metabolism</i> , 2017, 12, 199-205.	1.2	1
563	Acute and late complications after hypofractionated intensity modulated radiotherapy in prostate cancer. <i>Japanese Journal of Radiology</i> , 2017, 35, 269-278.	1.0	8
564	Extreme hypofractionation for high-risk prostate cancer: Dosimetric correlations with rectal bleeding. <i>Practical Radiation Oncology</i> , 2017, 7, e457-e462.	1.1	11
565	Stereotactic Body Radiotherapy. <i>Medical Radiology</i> , 2017, , 323-395.	0.0	0
566	Hydrogel rectum-prostate spacers mitigate the uncertainties in proton relative biological effectiveness associated with anterior-oblique beams. <i>Acta Oncologica</i> , 2017, 56, 575-581.	0.8	14
567	Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer. <i>Seminars in Radiation Oncology</i> , 2017, 27, 268-278.	1.0	45
569	Dosimetric Comparison and Evaluation of 4 Stereotactic Body Radiotherapy Techniques for the Treatment of Prostate Cancer. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 238-245.	0.8	20

#	ARTICLE	IF	CITATIONS
570	The Role of Hypofractionated Radiotherapy in Prostate Cancer. <i>Current Oncology Reports</i> , 2017, 19, 30.	1.8	50
571	A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases. <i>Physics in Medicine and Biology</i> , 2017, 62, 2859-2870.	1.6	6
572	The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer. <i>Cancer</i> , 2017, 123, 2945-2954.	2.0	9
573	Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 722-731.	0.4	38
574	Stereotactic ablative body radiosurgery (SABR) or Stereotactic body radiation therapy (SBRT). <i>Advanced Drug Delivery Reviews</i> , 2017, 109, 3-14.	6.6	75
575	Postoperative Radiation After Radical Prostatectomy. <i>Seminars in Radiation Oncology</i> , 2017, 27, 50-66.	1.0	4
576	Stereotactic Body Radiotherapy for Prostate Cancer. , 2017, , 307-317.		0
577	Hypofractionated Radiotherapy in Genitourinary Cancer: Better with Less. <i>Medical Radiology</i> , 2017, , 241-256.	0.0	0
579	Optimization of radiotherapy fractionation schedules based on radiobiological functions. <i>British Journal of Radiology</i> , 2017, 90, 20170400.	1.0	8
581	Conventional Versus Hypofractionated Radiation Therapy for Localized or Locally Advanced Prostate Cancer: A Systematic Review and Meta-analysis along with Therapeutic Implications. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 573-589.	0.4	60
582	Spatiotemporally Optimal Fractionation in Radiotherapy. <i>INFORMS Journal on Computing</i> , 2017, 29, 422-437.	1.0	16
583	Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer. <i>Radiotherapy and Oncology</i> , 2017, 124, 56-60.	0.3	75
584	Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. <i>European Urology</i> , 2017, 71, 766-773.	0.9	83
585	Stereotactic Body Radiation Therapy (SBRT) or Alternative Fractionation Schedules. <i>Cancer Drug Discovery and Development</i> , 2017, , 171-202.	0.2	0
586	Increasing the Therapeutic Ratio of Radiotherapy. <i>Cancer Drug Discovery and Development</i> , 2017, , .	0.2	2
587	What does large randomized trials tell us about the fractionation sensitivity of prostate cancer?. <i>Journal of Physics: Conference Series</i> , 2017, 777, 012024.	0.3	2
588	Recent advances in radiation oncology. <i>Ecancermedalscience</i> , 2017, 11, 785.	0.6	79
589	The Future of Altered Fractionation. <i>Medical Radiology</i> , 2017, , 41-63.	0.0	0



#	ARTICLE	IF	CITATIONS
590	Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1884-1890.	0.8	521
591	Are We Now Able to Define Guidelines for Moderate Hypofractionation in Prostate Cancer Radiation Therapy?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 871-873.	0.4	7
592	Recent advances in radiation oncology: multimodal targeting of high risk and recurrent prostate cancer. <i>Current Opinion in Oncology</i> , 2018, 30, 165-171.	1.1	1
593	Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer. <i>Advances in Radiation Oncology</i> , 2018, 3, 322-330.	0.6	14
594	Normal tissue damage: its importance, history and challenges for the future. <i>British Journal of Radiology</i> , 2019, 92, 20180048.	1.0	12
595	Variations in dosimetric distribution and plan complexity with collimator angles in hypofractionated volumetric arc radiotherapy for treating prostate cancer. <i>Journal of Applied Clinical Medical Physics</i> , 2018, 19, 93-102.	0.8	9
596	Moderate hypofractionation for prostate cancer: A user's guide. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018, 62, 232-239.	0.9	11
597	Clinical estimation of $\hat{\alpha}/\hat{\beta}^2$ values for prostate cancer from isoeffective phase III randomized trials with moderately hypofractionated radiotherapy. <i>Acta Oncologica</i> , 2018, 57, 883-894.	0.8	19
598	Safety and feasibility of prostate stereotactic ablative radiotherapy using multi-modality imaging and flattening filter free. <i>British Journal of Radiology</i> , 2018, 91, 20170625.	1.0	4
599	Prostate cancer high dose-rate brachytherapy: review of evidence and current perspectives. <i>Expert Review of Medical Devices</i> , 2018, 15, 71-79.	1.4	21
600	Moderately hypofractionated prostate external-beam radiotherapy: an emerging standard. <i>British Journal of Radiology</i> , 2018, 91, 20170807.	1.0	12
601	Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer. <i>Advances in Radiation Oncology</i> , 2018, 3, 163-169.	0.6	2
602	Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule: a systematic review. <i>Prostate International</i> , 2018, 6, 75-87.	1.2	39
603	Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 269-276.	2.0	22
604	Clinical analysis of the approximate, 3-dimensional, biological effective dose equation in multiphase treatment plans. <i>Medical Dosimetry</i> , 2018, 43, 11-22.	0.4	1
605	Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15-01). <i>Radiation Oncology</i> , 2018, 13, 230.	1.2	13
606	Stereotactic ablative body radiotherapy in patients with prostate cancer. <i>Translational Andrology and Urology</i> , 2018, 7, 330-340.	0.6	8
608	Analysis of Motion-dependent Clinical Outcome of Tumor Tracking Stereotactic Body Radiotherapy for Prostate Cancer. <i>Journal of Korean Medical Science</i> , 2018, 33, e107.	1.1	11

#	ARTICLE	IF	CITATIONS
610	Advances in Radiotherapy for Prostate Cancer Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1096, 31-47.	0.8	41
611	Phase I study of dose escalation to dominant intraprostatic lesions using high-dose-rate brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2018, 10, 193-201.	0.4	12
612	Intensity-modulated radiotherapy for prostate cancer. <i>Translational Andrology and Urology</i> , 2018, 7, 297-307.	0.6	33
613	Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 287-295.	0.4	62
614	Automated patient-specific transperineal ultrasound probe setups for prostate cancer patients undergoing radiotherapy. <i>Medical Physics</i> , 2018, 45, 3185-3195.	1.6	3
615	Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. <i>European Urology</i> , 2018, 74, 455-462.	0.9	250
616	Moderate hypofractionation for prostate cancer. <i>Translational Andrology and Urology</i> , 2018, 7, 321-329.	0.6	5
617	Hypofractionated external beam radiation therapy in combination with HDR boost for localized prostate cancer: patient reported quality of life outcomes. <i>Journal of Contemporary Brachytherapy</i> , 2018, 10, 211-217.	0.4	6
618	First fully automated planning solution for robotic radiosurgery – comparison with automatically planned volumetric arc therapy for prostate cancer. <i>Acta Oncologica</i> , 2018, 57, 1490-1498.	0.8	24
619	Stereotactic Body Radiotherapy for Primary Prostate Cancer. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381878963.	0.8	16
620	Long-term Outcomes of Radiotherapy Regimen of 72 Gy in 30 Fractions for Prostate Cancer. <i>Anticancer Research</i> , 2018, 38, 4207-4212.	0.5	2
621	The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. <i>Radiation Oncology</i> , 2018, 13, 96.	1.2	301
622	Science in Focus: Biological Optimisation of Radiotherapy Fraction Size in an Era of Immune Oncology. <i>Clinical Oncology</i> , 2018, 30, 605-608.	0.6	6
623	Exploration and application of phenomenological RBE models for proton therapy. <i>Physics in Medicine and Biology</i> , 2018, 63, 185013.	1.6	86
624	A pilot study of highly hypofractionated intensity-modulated radiation therapy over 3 weeks for localized prostate cancer. <i>Journal of Radiation Research</i> , 2018, 59, 656-663.	0.8	4
625	Radiobiological parameters in a tumour control probability model for prostate cancer LDR brachytherapy. <i>Physics in Medicine and Biology</i> , 2018, 63, 135011.	1.6	3
626	Genitourinary and gastrointestinal toxicity among patients with localized prostate cancer treated with conventional versus moderately hypofractionated radiation therapy: systematic review and meta-analysis. <i>Acta Oncologica</i> , 2018, 57, 1003-1010.	0.8	18
627	High efficacy of hypofractionated proton therapy with 4 fractions of 5 Gy as a boost to 50 Gy photon therapy for localized prostate cancer. <i>Radiotherapy and Oncology</i> , 2019, 141, 164-173.	0.3	6

#	ARTICLE	IF	CITATIONS
628	Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes. <i>Radiation Oncology</i> , 2019, 14, 136.	1.2	36
629	Moderate hypofractionated helical tomotherapy for localized prostate cancer: preliminary report of an observational prospective study. <i>Tumori</i> , 2019, 105, 516-523.	0.6	8
630	Biophysical modeling and experimental validation of relative biological effectiveness (RBE) for 4He ion beam therapy. <i>Radiation Oncology</i> , 2019, 14, 123.	1.2	37
631	Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2547-2554.	1.2	26
632	Charged Particle Stereotactic Body Radiation Therapy. , 2019, , 217-233.		0
633	Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 713-722.	0.4	29
634	Hypofractionated Intensity-modulated Radiotherapy for Intermediate- and High-risk Prostate Cancer: A Retrospective Study. <i>In Vivo</i> , 2019, 33, 1235-1241.	0.6	3
635	Sexual Function in Patients Treated With Stereotactic Radiotherapy For Prostate Cancer: A Systematic Review of the Current Evidence. <i>Journal of Sexual Medicine</i> , 2019, 16, 1409-1420.	0.3	24
636	Technological evolution of radiation treatment: Implications for clinical applications. <i>Seminars in Oncology</i> , 2019, 46, 193-201.	0.8	29
637	The evolving role of external beam radiotherapy in localized prostate cancer. <i>Seminars in Oncology</i> , 2019, 46, 246-253.	0.8	10
638	Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , The, 2019, 20, 1531-1543.	5.1	362
639	A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer. <i>Radiation Oncology</i> , 2019, 14, 158.	1.2	7
641	Three Discipline Collaborative Radiation Therapy (3DCRT) Special Debate: I would treat prostate cancer with proton therapy. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 7-14.	0.8	1
642	High-dose-rate brachytherapy as monotherapy for prostate cancer: The impact of cellular repair and source decay. <i>Brachytherapy</i> , 2019, 18, 701-710.	0.2	9
643	Influence of SBRT fractionation on TCP and NTCP estimations for prostate cancer. <i>Physica Medica</i> , 2019, 62, 41-46.	0.4	6
645	Applying a variable relative biological effectiveness (RBE) might affect the analysis of clinical trials comparing photon and proton therapy for prostate cancer. <i>Physics in Medicine and Biology</i> , 2019, 64, 115027.	1.6	12
646	An extended dose-volume model in high dose-rate brachytherapy – Using mean tail dose to reduce tumor underdosage. <i>Medical Physics</i> , 2019, 46, 2556-2566.	1.6	8
647	Prostate cancer dose-response, fractionation sensitivity and repopulation parameters evaluation from 25 international radiotherapy outcome data sets. <i>British Journal of Radiology</i> , 2019, 92, 20180823.	1.0	7

#	ARTICLE	IF	CITATIONS
648	Long-term outcome of hypofractionated intensity-modulated radiotherapy using TomoTherapy for localized prostate cancer: A retrospective study. PLoS ONE, 2019, 14, e0211370.	1.1	6
649	Reduced motion and improved rectal dosimetry through endorectal immobilization for prostate stereotactic body radiotherapy. British Journal of Radiology, 2019, 92, 20190056.	1.0	15
650	Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity. British Journal of Radiology, 2019, 92, 20190021.	1.0	6
651	Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 104, 325-333.	0.4	23
652	Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA Network Open, 2019, 2, e188006.	2.8	221
653	Hypofractionation for clinically localized prostate cancer. The Cochrane Library, 2019, 2019, CD011462.	1.5	28
654	The role of hypofractionated radiotherapy for the definitive treatment of localized prostate cancer: early results of a randomized trial. Journal of Cancer, 2019, 10, 6217-6224.	1.2	5
655	Quantitative MRI Changes During Weekly Ultra-Hypofractionated Prostate Cancer Radiotherapy With Integrated Boost. Frontiers in Oncology, 2019, 9, 1264.	1.3	16
656	A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate. Frontiers in Oncology, 2019, 9, 1378.	1.3	20
657	Analysis of radiosensitivity of cancer stem-like cells derived from canine cancer cell lines. Veterinary and Comparative Oncology, 2019, 17, 119-129.	0.8	4
658	Clinical outcome of high dose rate brachytherapy with external beam radiotherapy for high-risk prostate cancer: a single institutional retrospective study. Japanese Journal of Clinical Oncology, 2019, 49, 87-91.	0.6	1
659	Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionation. Radiation Oncology, 2019, 14, 4.	1.2	15
660	Stereotactic Radiosurgery for Prostate Cancer. , 2019, , .		1
661	Optimal number and sizes of the doses in fractionated radiotherapy according to the LQ model. Mathematical Medicine and Biology, 2019, 36, 1-53.	0.8	7
662	Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer: A Meta-analysis of Randomized Noninferiority Trials. European Urology Focus, 2019, 5, 577-584.	1.6	31
663	Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study. Pathology and Oncology Research, 2020, 26, 905-912.	0.9	15
664	Gantry-Mounted Linear Accelerator-Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer. Advances in Radiation Oncology, 2020, 5, 404-411.	0.6	6
665	Stereotactic Body Radiation Therapy to the Prostate Bed: Results of a Phase 1 Dose-Escalation Trial. International Journal of Radiation Oncology Biology Physics, 2020, 106, 537-545.	0.4	28

#	ARTICLE	IF	CITATIONS
666	Progress in Low Dose Rate Brachytherapy for Prostate Cancer. <i>Seminars in Radiation Oncology</i> , 2020, 30, 39-48.	1.0	9
667	Novel knowledge-based treatment planning model for hypofractionated radiotherapy of prostate cancer patients. <i>Physica Medica</i> , 2020, 69, 36-43.	0.4	16
668	Patient and physician reported toxicity with two-fraction definitive high-dose-rate prostate brachytherapy: the impact of implant interval. <i>Journal of Contemporary Brachytherapy</i> , 2020, 12, 216-224.	0.4	4
670	Margin verification for hypofractionated prostate radiotherapy using a novel dose accumulation workflow and iterative CBCT. <i>Physica Medica</i> , 2020, 77, 154-159.	0.4	11
671	Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer. <i>Radiation Oncology</i> , 2020, 15, 217.	1.2	6
672	Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR). <i>Radiation Oncology</i> , 2020, 15, 234.	1.2	5
674	Dosimetric effects of adaptive prostate cancer radiotherapy in an MR-linac workflow. <i>Radiation Oncology</i> , 2020, 15, 168.	1.2	24
675	Stereotactic body radiotherapy for localized prostate cancer – 5-year efficacy results. <i>Radiation Oncology</i> , 2020, 15, 173.	1.2	14
676	Hypofractionated Postoperative Radiotherapy for Prostate Cancer: Is the Field Ready Yet?. <i>European Urology Open Science</i> , 2020, 22, 9-16.	0.2	8
677	Clinical outcomes of definitive whole pelvic radiotherapy for clinical lymph node metastatic prostate cancer. <i>Cancer Medicine</i> , 2020, 9, 6629-6637.	1.3	8
678	Hypofractionated Prostate Radiation Therapy: Adoption and Dosimetric Adherence Through Clinical Pathways in an Integrated Oncology Network. <i>JCO Oncology Practice</i> , 2021, 17, e537-e547.	1.4	3
679	RBE variation in prostate carcinoma cells in active scanning proton beams: In-vitro measurements in comparison with phenomenological models. <i>Physica Medica</i> , 2020, 77, 187-193.	0.4	8
680	Stereotactic body radiotherapy (SBRT) in metachronous oligometastatic prostate cancer: a systematic review and meta-analysis on the current prospective evidence. <i>British Journal of Radiology</i> , 2020, 93, 20200496.	1.0	15
681	Ablative Radiotherapy in Prostate Cancer: Stereotactic Body Radiotherapy and High Dose Rate Brachytherapy. <i>Cancers</i> , 2020, 12, 3606.	1.7	6
682	Clinical implications of variable relative biological effectiveness in proton therapy for prostate cancer. <i>Acta Oncologica</i> , 2020, 59, 1171-1177.	0.8	3
683	Interstitial high-dose-rate brachytherapy as a boost in synchronous prostate and rectal cancer treatment: case report and literature review. <i>Journal of Contemporary Brachytherapy</i> , 2020, 12, 181-187.	0.4	0
684	Stereotactic Body Radiotherapy for Prostate Cancer. <i>American Journal of Men's Health</i> , 2020, 14, 155798832092724.	0.7	4
685	Translating the Immunobiology of SBRT to Novel Therapeutic Combinations for Advanced Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 830.	1.3	6

#	ARTICLE	IF	CITATIONS
686	A Prospective Multi-Institutional Phase I/II Trial of Step-Wise Dose-per-Fraction Escalation in Low and Intermediate Risk Prostate Cancer. <i>Practical Radiation Oncology</i> , 2020, 10, 345-353.	1.1	1
687	Modern development of high-dose-rate brachytherapy. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 490-501.	0.6	2
688	Applications of Nonlinear Programming to the Optimization of Fractionated Protocols in Cancer Radiotherapy. <i>Information (Switzerland)</i> , 2020, 11, 313.	1.7	3
689	Effect of reoxygenation on hypofractionated radiotherapy of prostate cancer. <i>Medical Physics</i> , 2020, 47, 5383-5391.	1.6	9
690	Three discipline collaborative radiation therapy (3DCRT) special debate: We should treat all cancer patients with hypofractionation. <i>Journal of Applied Clinical Medical Physics</i> , 2020, 21, 7-14.	0.8	4
691	Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 299-304.	0.4	37
692	Progress towards Patient-Specific, Spatially-Continuous Radiobiological Dose Prescription and Planning in Prostate Cancer IMRT: An Overview. <i>Cancers</i> , 2020, 12, 854.	1.7	7
693	Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials. <i>Radiotherapy and Oncology</i> , 2020, 148, 235-242.	0.3	33
694	Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancer. <i>Radiotherapy and Oncology</i> , 2020, 147, 123-129.	0.3	10
695	Prostate bed and organ-at-risk deformation: Prospective volumetric and dosimetric data from a phase II trial of stereotactic body radiotherapy after radical prostatectomy. <i>Radiotherapy and Oncology</i> , 2020, 148, 44-50.	0.3	14
696	Stereotactic Body Radiotherapy Using CyberKnife® for Localized Low- and Intermediate-risk Prostate Cancer: Initial Report on a Phase I/II Trial. <i>Anticancer Research</i> , 2020, 40, 2053-2057.	0.5	2
697	Two-year outcomes of moderately hypofractionated 70 Gy in 28 fractions, intensity-modulated radiotherapy and volumetric modulated arc therapy for localised prostate cancer. <i>Journal of Radiotherapy in Practice</i> , 2021, 20, 242-244.	0.2	0
698	Standard versus hypofractionated intensity-modulated radiotherapy for prostate cancer: assessing the impact on dose modulation and normal tissue effects when using patient-specific cancer biology. <i>Physics in Medicine and Biology</i> , 2021, 66, 045007.	1.6	2
699	Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 133-140.	1.0	6
700	Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. <i>Radiotherapy and Oncology</i> , 2021, 154, 207-213.	0.3	24
701	Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 227-236.	0.4	23
702	Ultrahypofractionation of localized prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 89-96.	1.0	22
703	Dosimetric Predictors of Genitourinary Toxicity From a Phase I Trial of Prostate Bed Stereotactic Body Radiation Therapy. <i>Practical Radiation Oncology</i> , 2021, 11, e90-e97.	1.1	3

#	ARTICLE	IF	CITATIONS
704	Toward <i>in vivo</i> Dosimetry for Prostate Radiotherapy With a Transperineal Ultrasound Array: A Simulation Study. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2021, 5, 373-382.	2.7	8
705	Moderate hypofractionated post-prostatectomy radiation therapy is feasible and well tolerated: experience from a single tertiary cancer centre. <i>Clinical and Translational Oncology</i> , 2021, 23, 1452-1462.	1.2	2
706	Potential Clinical Significance of Overall Targeting Accuracy and Motion Management in the Treatment of Tumors That Move With Respiration: Lessons Learnt From a Quarter Century of Stereotactic Body Radiotherapy From Dose Response Models. <i>Frontiers in Oncology</i> , 2020, 10, 591430.	1.3	4
707	Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review. <i>Cancers</i> , 2021, 13, 759.	1.7	18
708	Using CT-guided stereotactic prostate radiation therapy (CT-SPRT) to assess sustained murine prostate ablation. <i>Scientific Reports</i> , 2021, 11, 6571.	1.6	0
709	Outcomes of Patients With Spinal Metastases From Prostate Cancer Treated With Conventionally-Fractionated External Beam Radiation Therapy. <i>Global Spine Journal</i> , 2021, , 219256822199479.	1.2	1
710	Feeding the Controversy: When Pelvic Irradiation Improves Outcomes in High-Risk and Very High-Risk Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1196-1202.	0.8	0
711	Dosimetric impact of rectum and bladder anatomy and intrafractional prostate motion on hypofractionated prostate radiation therapy. <i>Clinical and Translational Oncology</i> , 2021, 23, 2293-2301.	1.2	2
712	The one hundred most cited publications in prostate brachytherapy. <i>Brachytherapy</i> , 2021, 20, 611-623.	0.2	1
713	Institute for Clinical and Economic Review. , 2021, , 112-141.		0
714	Optimizing External Beam Radiotherapy as per the Risk Group of Localized Prostate Cancer: A Nationwide Multi-Institutional Study (KROG 18-15). <i>Cancers</i> , 2021, 13, 2732.	1.7	1
715	Phase II study of stereotactic body radiotherapy with hydrogel spacer for prostate cancer: acute toxicity and propensity score-matched comparison. <i>Radiation Oncology</i> , 2021, 16, 107.	1.2	6
716	Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa). <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021, 25, 400-409.	0.6	2
717	Interfractional Geometric Variations and Dosimetric Benefits of Stereotactic MRI Guided Online Adaptive Radiotherapy (SMART) of Prostate Bed after Radical Prostatectomy: Post-Hoc Analysis of a Phase II Trial. <i>Cancers</i> , 2021, 13, 2802.	1.7	11
718	Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study. <i>Radiation and Oncology</i> , 2021, 55, 474-481.	0.6	1
719	Assessing the relative biological effectiveness of high-dose rate <sup>60</sup> Co brachytherapy alone and in combination with cisplatin treatment on a cervical cancer cell line (HeLa). <i>Radiation Physics and Chemistry</i> , 2021, 184, 109465.	1.4	1
720	Patient reported toxicity and quality of life after hypofractionated high-dose intensity-modulated radiotherapy for intermediate- and high risk prostate cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 29, 40-46.	0.9	4
721	Highly hypofractionated intensity-modulated radiation therapy for nonmetastatic prostate cancer with a simultaneous integrated boost to intraprostatic lesions: a planning study. <i>Japanese Journal of Radiology</i> , 2022, 40, 210-218.	1.0	1

#	ARTICLE	IF	CITATIONS
722	Salvage therapy for prostate cancer after radical prostatectomy. <i>Nature Reviews Urology</i> , 2021, 18, 643-668.	1.9	26
723	The Organ Sparing Potential of Different Biological Optimization Strategies in Proton Therapy. <i>Advances in Radiation Oncology</i> , 2021, 6, 100776.	0.6	5
724	Prostate hypofractionated radiotherapy (62Gy at 3.1Gy per fraction) with injection of hyaluronic acid: final results of the RPAH1 study. <i>British Journal of Radiology</i> , 2021, 94, 20210242.	1.0	3
725	Treatment Strategies for High-Risk Localized and Locally Advanced and Oligometastatic Prostate Cancer. <i>Cancers</i> , 2021, 13, 4470.	1.7	6
726	Five-year outcomes of stereotactic body radiation therapy (SBRT) for prostate cancer: the largest experience in China. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3557-3564.	1.2	5
727	Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost. <i>Current Oncology</i> , 2021, 28, 3474-3487.	0.9	4
728	The effectiveness of high-dose-rate brachytherapy with external beam radiotherapy for clinically locally advanced and node-positive prostate cancer: long-term results of a retrospective study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2310-2317.	1.0	2
729	Clinical Outcomes of the CHIRP Trial: A Phase II Prospective Randomized Trial of Conventionally Fractionated Versus Moderately Hypofractionated Prostate and Pelvic Nodal Radiation Therapy in Patients With High-Risk Prostate Cancer. <i>Practical Radiation Oncology</i> , 2021, 11, 384-393.	1.1	12
730	Retrospective comparison of rectal toxicity between carbon-ion radiotherapy and intensity-modulated radiation therapy based on treatment plan, normal tissue complication probability model, and clinical outcomes in prostate cancer. <i>Physica Medica</i> , 2021, 90, 6-12.	0.4	2
731	Prostate IMRT. , 2006, , 391-410.		3
732	Radiation Therapy in Prostate Cancer. , 2007, 175, 179-199.		4
733	Tumor Biology's Impact on Clinical Cure Rates. <i>Medical Radiology</i> , 2009, , 323-334.	0.0	6
735	Radiobiology of Prostate Cancer. , 2012, , 79-101.		4
736	High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer. , 2019, , 181-197.		1
737	Fractionation Effects in Clinical Practice. , 2010, , 40-54.		1
738	Cancer of the Prostate. , 2010, , 925-986.		2
739	Dosimetric comparison among cyberknife, helical tomotherapy and VMAT for hypofractionated treatment in localized prostate cancer. <i>Medicine (United States)</i> , 2020, 99, e23574.	0.4	11
740	The linear-quadratic approach in clinical practice. , 2009, , 120-134.		43



#	ARTICLE	IF	CITATIONS
741	Walking Forward: The South Dakota Native American Project. <i>Journal of Cancer Education</i> , 2005, 20, 65-70.	0.6	29
742	Dosimetric Evaluation for Various Methods of Combined Radiotherapy of Cervical Cancer. <i>Medical Radiology and Radiation Safety</i> , 2019, 64, 45-52.	0.0	1
744	Moderate hypofractionated radiotherapy is more effective and safe for localized prostate cancer patients: a meta-analysis. <i>Oncotarget</i> , 2017, 8, 2647-2658.	0.8	10
745	Moderate hypofractionation for prostate cancer. <i>Oncotarget</i> , 2017, 8, 84612-84613.	0.8	1
746	Stereotactic body radiation therapy for prostate cancer: systematic review and meta-analysis of prospective trials. <i>Oncotarget</i> , 2019, 10, 5660-5668.	0.8	11
747	Neurovascular Bundle Infiltration Can Explain Local Relapses Using Conformal Radiotherapy of Prostate Cancer. <i>Anticancer Research</i> , 2017, 37, 1825-1830.	0.5	2
748	Impact of prolonged fraction dose-delivery time modeling intensity-modulated radiation therapy on hepatocellular carcinoma cell killing. <i>World Journal of Gastroenterology</i> , 2005, 11, 1452.	1.4	37
749	Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma. <i>Radiation Oncology Journal</i> , 2016, 34, 260-264.	0.7	10
750	A study on rectal dose measurement in phantom and in vivo using Gafchromic EBT3 film in IMRT and CyberKnife treatments of carcinoma of prostate. <i>Journal of Medical Physics</i> , 2013, 38, 132.	0.1	6
751	Dosimetric analysis and comparison of IMRT and HDR brachytherapy in treatment of localized prostate cancer. <i>Journal of Medical Physics</i> , 2010, 35, 113.	0.1	6
752	Isoeffect calculations with the linear quadratic and its extensions: An examination of model-dependent estimates at doses relevant to hypofractionation. <i>Journal of Medical Physics</i> , 2011, 36, 100.	0.1	3
753	Equivalent normalized total dose estimates in cyberknife radiotherapy dose delivery in prostate cancer hypofractionation regimens. <i>Journal of Medical Physics</i> , 2012, 37, 90.	0.1	4
754	Radiation Therapy Alone in cT1-3N0 Non-small Cell Lung Cancer Patients Who Are Unfit for Surgical Resection or Stereotactic Radiation Therapy: Comparison of Risk-Adaptive Dose Schedules. <i>Cancer Research and Treatment</i> , 2016, 48, 1187-1195.	1.3	12
755	Image-guided focal therapy for prostate cancer. <i>Diagnostic and Interventional Radiology</i> , 2014, 20, 492-497.	0.7	20
756	Review of Hypofractionated Radiotherapy for Prostate Cancer. <i>ISRN Oncology</i> , 2012, 2012, 1-5.	2.1	11
757	Early toxicity of hypofractionated radiotherapy for prostate cancer. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia</i> , 2016, 160, 435-441.	0.2	5
758	Comparison of Survival Between Hypofractionated and Conventional Radiotherapy in Clinically Localized Prostate Cancer: A Single-Center Retrospective Cohort. <i>International Journal of Cancer Management</i> , 2020, 13, .	0.2	1
759	Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry. <i>Cureus</i> , 2015, 7, e395.	0.2	25

#	ARTICLE	IF	CITATIONS
760	Salvage hypofractionated accelerated versus standard radiotherapy for the treatment of biochemical recurrence after radical prostatectomy (SHARE): the protocol of a prospective, randomized, open-label, superiority, multi-institutional trial. <i>Trials</i> , 2021, 22, 728.	0.7	1
761	The journey of radiotherapy dose escalation in high risk prostate cancer; conventional dose escalation to Stereotactic Body Radiotherapy (SBRT) boost treatments.. <i>Clinical Genitourinary Cancer</i> , 2021, , .	0.9	5
762	The Utrecht technique in RAPIDStrand TM afterloading. , 2005, , 404-408.		0
763	Radiobiological Considerations of Stereotactic Body Radiotherapy. , 2005, , 131-176.		0
766	MOâ€Dâ€BRAâ€02: Application of Hypofractionation in the Prostate. <i>Medical Physics</i> , 2007, 34, 2525-2525.	1.6	0
767	SUâ€GGâ€Tâ€427: Dose Painting to Combat Tumor Hypoxia While Sparing Urethra in Prostate IMRT: A Biologicallyâ€Based Adaptive Approach Accounting for Setup Uncertainties and Organ Motion. <i>Medical Physics</i> , 2008, 35, 2823-2823.	1.6	0
769	Stereotactic Body Radiation Therapy. , 2010, , 1594-1600.		0
770	Prostate SBRT. , 2011, , 287-298.		0
771	Clinical Usefulness of Implanted Fiducial Markers for Hypofractionated Radiotherapy of Prostate Cancer. <i>The Journal of the Korean Society for Therapeutic Radiology and Oncology</i> , 2011, 29, 91.	0.1	1
772	Hypofractionated Radiation Therapy in Prostate Cancer: Rationale, History, and Outcomes. , 2012, , 103-118.		0
773	Stereotactic Treatment for Prostate Cancer: An Overview. , 2012, , 133-140.		0
774	Patient Selection for Robotic Radiosurgery for Clinically Localized Prostate Cancer: Come One, Come All. , 2012, , 165-175.		1
775	Fractionation and altered fractionation in radiotherapy. , 2012, , 107-128.		0
776	Intensity Modulated Radiotherapy for Prostate Cancer. , 2012, , 143-155.		0
778	Problems to Be Solved in Molecular Oncology. , 2012, , 237-252.		0
780	Proton Beam Therapy and Novel Radiotherapeutic Approaches to the Treatment of Prostate Cancer. , 2013, , 761-771.		0
781	Prostate Brachytherapy: High Dose Rate. , 2013, , 739-748.		1
782	Pulsed-Dose Rate Brachytherapy in Prostate Cancer. , 2013, , 111-117.		0

#	ARTICLE	IF	CITATIONS
783	Dosimetric comparison of Stereotactic body radiotherapy and Intensity modulated radiotherapy to deliver hypofractionated radiotherapy in organ confined prostate cancer. <i>Cureus</i> , 2013, , .	0.2	0
784	Stereotaktyczna hypofrakcjonowana radioterapia chorych na raka gruczołu krokowego – doniesienie wstępne. <i>Nowotwory</i> , 2014, 64, 16-23.	0.1	0
785	Brachytherapy. , 2015, , 79-96.		0
786	Prostate Stereotactic Body Radiotherapy – Methods, Rationale, Outcomes, and Future Directions. , 2015, , 195-224.		0
788	A Report on the Clinical Outcome after High-Dose Rate (HDR) Brachytherapy as Monotherapy in Early Prostate Cancer. <i>Cureus</i> , 2015, 7, e303.	0.2	5
789	Stereotactic Body Radiotherapy Using Cyberknife for Localized Prostate Cancer. <i>Reports of Radiotherapy &amp; Oncology</i> , 2015, In Press, .	0.1	0
790	Prostate: High-Dose Rate Brachytherapy in the Treatment of Clinically Organ-Confined Prostate Cancer. <i>Medical Radiology</i> , 2016, , 319-343.	0.0	0
791	The Generation of Quantitative Radiobiology Data. , 2016, , 27-36.		0
792	The Radiosensitivity of Tumor Cells In Vitro versus In Vivo. , 2016, , 103-112.		0
794	Postoperative Hypofractionated Radiation Therapy in Prostate Carcinoma: A Systematic Review. <i>Anticancer Research</i> , 2018, 38, 1221-1230.	0.5	10
795	Japanese Brachytherapy in the World. , 2019, , 11-22.		0
796	Treatment Planning Considerations for Prostate SBRT and MRI Based Planning. , 2019, , 17-41.		0
797	Overview of Tumor Control Outcomes with Prostate SBRT for Low and Intermediate Risk Prostate Cancer and Comparison to Other Treatment Interventions. , 2019, , 93-110.		0
798	Dose Escalation for Prostate Cancer Using Oligofractionated, Stereotactic Ablative Radiotherapy. , 2019, , 183-196.		0
799	SBRT for High-Risk Prostate Cancer. , 2019, , 153-169.		0
800	Radiobiological Evaluation of Dosimetric Plans for Stereotactic Radiotherapy for Prostate Cancer According to Fractionation Regimen. <i>Vestnik Rentgenologii i Radiologii</i> , 2019, 100, 263-269.	0.1	2
801	Acute toxicities after extremely hypofractionated radiotherapy for prostate cancer: lessons from HYPO-RT-PC and PACE-B. <i>Translational Cancer Research</i> , 2020, 9, 4469-4472.	0.4	2
802	Stereotactic body radiotherapy as a boost after external beam radiotherapy for high-risk prostate cancer patients. <i>Indian Journal of Cancer</i> , 2020, .	0.2	1

#	ARTICLE	IF	CITATIONS
804	Radical Radiotherapy for Prostate Cancer. , 2007, , 1-23.		0
806	Simulation of an HDR "Boost" with Stereotactic Proton versus Photon Therapy in Prostate Cancer: A Dosimetric Feasibility Study. International Journal of Particle Therapy, 2021, 7, 11-23.	0.9	0
809	The case for hypofractionation of localized prostate cancer. Reviews in Urology, 2013, 15, 113-7.	0.9	9
810	Hypofractionated radiation therapy for prostate cancer: biologic and technical considerations. American Journal of Clinical and Experimental Urology, 2014, 2, 286-93.	0.4	8
811	Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond. Radiotherapy and Oncology, 2022, 166, 1-7.	0.3	9
812	HERMES: Delivery of a Speedy Prostate Cancer Treatment. Clinical Oncology, 2022, 34, 426-429.	0.6	14
813	Seminal vesicle inter- and intra-fraction motion during radiotherapy for prostate cancer: A review. Radiotherapy and Oncology, 2022, 169, 15-24.	0.3	8
814	Injection of hydrogel spacer increased maximal intrafractional prostate motion in anterior and superior directions during volumetric modulated arc therapy-stereotactic body radiation therapy for prostate cancer. Radiation Oncology, 2022, 17, 41.	1.2	0
815	Long-Term Outcomes of Dose-Escalated Hypofractionated Radiotherapy in Localized Prostate Cancer. Biology, 2022, 11, 435.	1.3	0
816	Variability of $\hat{\mu}/\hat{\sigma}^2$ ratios for prostate cancer with the fractionation schedule: caution against using the linear-quadratic model for hypofractionated radiotherapy. Radiation Oncology, 2022, 17, 54.	1.2	4
817	Urethra Sparing With Target Motion Mitigation in Dose-Escalated Extreme Hypofractionated Prostate Cancer Radiotherapy: 7-Year Results From a Phase II Study. Frontiers in Oncology, 2022, 12, 863655.	1.3	3
818	Assessing Commercial CLEANBOLUS Based on Silicone for Clinical Use. Progress in Medical Physics, 2021, 32, 159-164.	0.5	0
819	Meta-analysis of Elective Pelvic Nodal Irradiation Using Moderate Hypofractionation for High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 113, 1044-1053.	0.4	5
820	Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial. Radiation Oncology, 2022, 17, 75.	1.2	10
821	Reducing ExacTrac intrafraction imaging uncertainty for prostate stereotactic body radiotherapy using a pre-treatment CBCT. Physical and Engineering Sciences in Medicine, 2022, , .	1.3	1
823	Hypofractionated intensity-modulated simultaneous integrated boost and image-guided radiotherapy in the treatment of high-risk prostate cancer patients: a preliminary report on acute toxicity. Tumori, 2013, 99, 474-9.	0.6	3
824	Propensity score-matched analysis comparing dose-escalated intensity-modulated radiation therapy versus external beam radiation therapy plus high-dose-rate brachytherapy for localized prostate cancer. Strahlentherapie Und Onkologie, 2022, , 1.	1.0	4
825	Modulation of Peripheral Immune Cell Subpopulations After RapidArc/Moderate Hypofractionated Radiotherapy for Localized Prostate Cancer: Findings and Comparison With 3D Conformal/Conventional Fractionation Treatment. Frontiers in Oncology, 0, 12, .	1.3	4

#	ARTICLE	IF	CITATIONS
827	Acute and Late Rectal Toxicity Following Hypofractionated Radiotherapy in Patients With Prostate Cancer: Results of a Prospective Study. <i>In Vivo</i> , 2022, 36, 1875-1880.	0.6	1
828	Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 683-689.	1.0	4
829	Results of a prospective randomized trial on long-term effectiveness of protons and carbon ions in prostate cancer: LEM I and $\hat{I}^2\hat{A}=\hat{A}^2\hat{G}y$ overestimates the RBE. <i>Radiotherapy and Oncology</i> , 2022, 173, 223-230.	0.3	5
830	Radiobiological analysis of preliminary results of a phase II study of pelvic hypofractionated and accelerated radiotherapy for high-risk prostate cancer patients. <i>Radiation Oncology Journal</i> , 2022, 40, 151-161.	0.7	0
831	Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 142-152.	0.4	21
832	Health-related quality of life of salvage prostate reirradiation using stereotactic ablative radiotherapy with urethral-sparing. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
833	Ultra-Hypofractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer: Clinical Outcomes, Patterns of Recurrence, Feasibility of Definitive Salvage Treatment, and Competing Oncological Risk. <i>Biomedicines</i> , 2022, 10, 2446.	1.4	3
835	Stereotactic prostate radiotherapy with or without androgen deprivation therapy, study protocol for a phase III, multi-institutional randomized-controlled trial. <i>BJR Open</i> , 2022, 4, .	0.4	1
836	Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States â€” Understanding the transition to adaptive, ultra-hypofractionated treatments. <i>Clinical and Translational Radiation Oncology</i> , 2023, 38, 161-168.	0.9	2
837	MR linac radiation therapy: A real-time personalized approach for prostate cancer. <i>Advances in Magnetic Resonance Technology and Applications</i> , 2023, , 341-365.	0.0	0
838	Preliminary Analysis of a Phase II Trial of Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features After Radical Prostatectomy. <i>Advances in Radiation Oncology</i> , 2023, 8, 101143.	0.6	4
839	Tenâ€”year outcomes of wholeâ€”pelvic intensityâ€”modulated radiation therapy for prostate cancer with regional lymph node metastasis. <i>Cancer Medicine</i> , 2023, 12, 7859-7867.	1.3	2
840	Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 116, 770-778.	0.4	4
841	Linac-based versus MR-guided SBRT for localized prostate cancer: a comparative evaluation of acute tolerability. <i>Radiologia Medica</i> , 0, , .	4.7	0
842	Patientâ€”specific voxelâ€”level dose prescription for prostate cancer radiotherapy considering tumor cell density and grade distribution. <i>Medical Physics</i> , 2023, 50, 3746-3761.	1.6	2
843	Treatment planning of carbon ion radiotherapy for prostate cancer based on cellular experiments with PC3 human prostate cancer cells. <i>Physica Medica</i> , 2023, 107, 102537.	0.4	2
844	Comparison of outcomes in high-risk prostate cancer patients treated with low-/high-dose-rate brachytherapy plus external beam radiotherapy. <i>International Journal of Clinical Oncology</i> , 2023, 28, 698-706.	1.0	3
845	Dose Distribution of High Dose-Rate and Low Dose-Rate Prostate Brachytherapy at Different Intervalsâ€”Impact of a Hydrogel Spacer and Prostate Volume. <i>Cancers</i> , 2023, 15, 1396.	1.7	1

#	ARTICLE	IF	CITATIONS
846	Retrospective Analysis of Clinical Outcomes of Stereotactic Body Radiation Therapy for Localized Prostate Cancer at an Asian Cancer Specialist Centre. <i>Asian Pacific Journal of Cancer Prevention</i> , 2023, 24, 545-550.	0.5	0
848	Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	3
849	Virtual clinical trial based on outcome modeling with iteratively redistributed extrapolation data. <i>Radiological Physics and Technology</i> , 2023, 16, 262-271.	1.0	1
850	Recent Advances in Radiotherapy Modalities for Prostate Cancer. <i>Acta Clinica Croatica</i> , 2022, , .	0.1	0
852	Radiation Therapies in Cancer. <i>Cancer Treatment and Research</i> , 2023, , 59-77.	0.2	0
862	The march toward single-fraction stereotactic body radiotherapy for localized prostate cancerâ€™ Quo Vadimus?. <i>World Journal of Urology</i> , 2023, 41, 3485-3491.	1.2	1
869	MRI-Guided Radiation Therapy for Prostate Cancer: Less Is More When Technology and Evidence Intersect. , 2024, , 285-305.		0